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Controlled release formulations improve drug safety and address patient adherence, barriers that 
are responsible for 10% of hospitalizations and over $100 billion in annual medical expenses.  
These benefits apply to medications that require consistent dosing over days, weeks, or months, a 
category accounting for over 90% of prescription drugs sales.   Yet, the use of controlled release 
formulations remains comparatively sparse because their design requires months of costly 
experimentation.    
Significant scholarship has been devoted to facilitating formulation development and to 
understanding controlled release behavior, particularly in the realm of mathematical modeling.  
However, each modeling study to date has only focused on predicting the performance of an 
extremely limited number of “drug”-polymer combinations, vehicle geometries and excipient 
types.  Researchers have yet to arrive at one general theory of controlled release applicable to a 
wide range of drug delivery systems and have even begun to doubt that one will be developed.   
To define the underlying mechanisms of controlled release, we studied data from 
formulations encapsulating a wide variety of agents.  Analysis began with poly(lactic-co-
glycolic) (PLGA) acid microparticles, yielding a set of equations that predicted the release 
behavior of neutral or anionic, water-soluble agents from small molecule drugs (~300Da) to 
viruses.  Building from this foundation, new layers of diffusion/reaction equations were added to 
enable predictions for implant systems and sparingly soluble drugs.  These predictions compared 
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 v 
favorably to in vitro data from implants that underwent either dissolution-limited or degradation-
controlled release.  
The new predictive models of controlled release enable analytical interpretation of in 
vitro release data.   Their predictions have identified rates and durations of drug release in over 
20 systems to date.  Calculations of in vitro release also aid in targeting precise release behaviors 
ranging abrupt bursts to sustained, constant release.  These behaviors were realized in a delayed 
release vaccine, capable of masking antigen from the body until a specific point in time, and as a 
sustained release formulation that delivered the HIV entry inhibitor, enfuvirtide, for one month. 
The in vitro and in vivo data from these two proof-of-concept applications support the use of 
predictive modeling in the design of long-acting controlled release formulations. 
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1.0  INTRODUCTION: 
1.1 CONTROLLED RELEASE TECHNOLOGY 
Controlled release technology is a collection of tools, methods, or indeed technologies, for 
autonomously delivering an encapsulated payload at a desirable rate or with desirable timing. 
Products that rely on controlled release technology are found today in agricultural, food, 
consumables, personal-care, and pharmaceutical industries.  Examples of these products include 
hormone supplements for cattle, nutrient-enriched drinks, microencapsulated enzymes in laundry 
detergents, moisturizing creams, and pills with once-daily dosing.  These products range from 
the incredibly simple, like sandwiched layers of flavor in chewing gum, to the molecularly 
complex, like enyzme-degradable polymers for bio-responsive drug release.   
1.1.1 Application to Drug Delivery  
From the diversity of controlled release products, the drug delivery applications clearly represent 
the largest market segment with over $20 billion in annual sales
7
.  In this niche, salts, sugars, 
polymers and other excipients are used to prolong bioavailability of a drug enabling less frequent 
administration.  Successfully controlled release medications can command over $1 billion in 
annual sales
8
.  Controlled release pills frequently reduce dosing from 2, 3, or 4 times a day to 
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once-daily.  Biodegradable polymer matrices, such as nanoparticles, microparticles, film coatings 
and implants, allow dosing to be extended even further. A single injection of biodegradable 
polymer microparticles can provide weeks or months of dosing.  An example of this type of 
medication is Risperdol Consta®, which provides two weeks of treatment for schizophrenic 
patients of whom fewer than 50% consume oral medications as prescribed
9
.  In addition to 
improving adherence, long-acting formulations can also enable entirely new types of treatments.  
Gliadel wafer® a biodegradable disc that releases carmustine provides a hallmark example of 
such a treatment, by enabling the local treatment of neural glioblastoma after surgical resection.  
Use of this medication increased patient lifespan by 19-39% in clinical trials
10
.   
1.1.2 Potential and Limitations  
The potential of controlled release medications, and in particular the long-acting dosage forms 
that provide weeks to months of drug delivery, is actually far greater than the size of the present 
controlled release technology market ($28 billion) indicates
7
.  Controlled release technology 
addresses patient non-compliance (the failure to adhere to a prescription), which is a significantly 
larger market, accounting for $136 billion in annual medical expenses
11
.  In practice, the field 
has not yet realized this enormous potential because generating a specific controlled release 
formulation (i.e. one customized to the dosing schedule demanded by any given medication) is 
extremely time consuming and costly.  As such, only 11 controlled release formulations that 
extend dosing beyond 1 week have reached the market
12
.  In each case, the associated drugs have 
clear compliance risks (elevating the need for extended dosing) or wide therapeutic windows 
(relaxing the requirement for stringent control over release).   Yet, these medications represent 
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just a small fraction of drugs that could be improved with properly designed controlled release 
formulations.  By one estimate, at least 90% of the top 100 best-selling prescription medications 
could further advance patient quality of life if they offered reduced dosing frequency
13,14
.  From 
this viewpoint, the field can be said to have broad therapeutic applicability, but comparatively 
limited implementation.  
1.1.2.1 Quality Assurance Considerations 
In addition to being notoriously difficult to design, long-acting controlled release formulations 
are noted as being among the most complex of drug formulations to successfully consistently 
produce. The production of a biodegradable microparticles formulation brings into play a 
number of quality control considerations, including the properties of polymers and excipients, 
the removal of organic solvents, the lyophilization of powdered product, and the assessment of 
needle gauge
15
.  Current practice is to assess the quality of a product batch post production.  The 
most time consuming portion of this analysis is the in vitro release assay where a formulation’s 
rate of drug release is measured in real time in order to determine if it is consistent with the FDA 
approved performance requirements.  Research has been conducted on methods of accelerating 
the in vitro release assay by the means of elevated temperature
16
.  For common hydrolysable 
polymers, such as poly(lactic-co-glycolic) acid, formulation degradation and in turn drug release 
is accelerated by increasing ambient temperature from 37
o
C (standard) to values of between 
40
o
C and 60
o
C.  Once correlated to data from assays conducted at 37
o
C, an elevated temperature 
assay can produce comparable results in a fraction of the time. At best, this approach has 
shortened the 2 month quality control assaying of Risperidol Consta® down to 1 week
17
.  
However, product safety and production efficiency can be further improved by a Quality by 
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Design (QbD) approach to quality control.  In QbD knowledge of how variation in a 
formulations composition and production will affect its performance is used to determine if a 
given product is acceptable.  This requires mapping of a formulation’s performance across a 
design space spanning changes in both process parameters, such as mixing speed or 
lyophilization time, and material properties, such as polymer molecular weight or excipient 
concentration
18
.  The state of the art in conducting such analysis is known as Design of 
Experiments (DoE), where statistical metrics are used to minimize the number of experiments 
needed to fully explore the combined impacts of various formulation properties and 
manufacturing parameters on drug release
19,20
. Even with the efficiency ensured by DoE, QbD 
analysis is very time consuming and costly to perform on long acting parenteral formulations 
because many different variations of a basic microparticle or implant design must be produced 
and then assayed over weeks or months until the full extent of their release behavior is known.     
1.1.2.2 Summary of long acting controlled release formulations 
Long acting formulations that deliver drug over weeks or months before being safely resorbed by 
the body are an area of tremendous potential for the field of controlled release technology.  Such 
formulations have already made medical impacts addressing patient compliance and enabling 
entirely new types of treatments.  They also have the potential to improve the large majority of 
medications, if cost and time issues associated with design and production can be addressed.  
Specific challenges come from an iterative experiment-driven design process and new quality 
assessment demands to improve formulation safety.  Both of these challenges could be resolved 
with an in-depth quantitative understanding of parameters that effect formulation function.   
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2.0  PRIOR ART IN THE EMPIRICAL DESIGN OF CONTROLLED RELEASE 
FORMULATIONS 
2.1 INTRODUCTION 
Bulk eroding biodegradable polymer matrices have a track record of FDA approval that extends 
back more than 40 years.  This record of clinical safety and efficacy encompasses not only long-
acting controlled release formulations, but also surgical sutures and implantable devices, such as 
resorbable bone screws.  Accordingly bulk-eroding polymer matrices, such as poly(lactic-co-
glycolic) acid (PLGA) microparticles remain a first-choice in scenarios where drug must be 
autonomously released over weeks or months.  However, because bulk eroding polymers, such 
as PLGA, were first developed for orthopedic and surgical applications, they are not optimally 
engineered for drug delivery performance.   
Over the past two decades, a number of studies have aimed to increase the efficiency of 
designing degradable polymer drug delivery formulations.  The earliest studies sought to identify 
key physical properties of the polymer matrices that determine release behavior
21,22
. Twenty 
years later, researchers are still experimenting with a variety of new formulation compositions, 
polymer chemistries and processing conditions in an attempt to tune this release behavior
23-26
.  
Over time, a number of system properties and processing conditions have emerged as potential 
tools for tuning the kinetics of delivery systems
14,27
.  However, a standardized method of tuning 
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remains elusive due to the complexity that arises when factors, such as polymer chemistry, alter 
several properties that determine release simultaneously, such as matrix crystallinity, pH, 
degradation rate and hydrophobicity
24
. 
A review of empirical tools is essential in order to understand what is known about how 
biodegradable polymer matrices function as controlled release formulations. The most widely-
studied biodegradable polymeric materials (i.e. polyesters, polyanhydrides, poly-ortho esters, 
etc…) offer the largest wealth of information on such tools given their long history of use and 
similarity of fundamental release behavior, which encompassed both the underlying mechanisms 
and resulting kinetics.  Although the techniques that can be used to control release in these 
systems are generally applicable to any size, shape, and orientation of a degradable matrix, this 
chapter will most often refer to one of the most commonly reported configurations of these 
matrices, a spherical particulate system.(Figure 1)  Studies on microparticles have empirically 
varied independent system properties (such as matrix size, degradation rate or polymer molecular 
weight) or processing conditions (such as emulsion type, solution osmolality, or solvent choice)  
 
Figure 1: Microscopy images of particle matrix cross-sections and exteriors (insert).   
A) In homogenous systems (like single emulsion microparticles) the drug resides in-phase with the polymer matrix 
(adapted with permission from
1
).  B) In contiguous systems (like double or water-in-oil-in-water emulsion 
microparticles), the drug resides in pockets that are separated from the polymer matrix. 
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and documented their effects with in vitro assays.  Each of these experimental variations can be 
evaluated for its potential as a design tool that a engineer can use to tune release behavior. 
As a general rule, drug delivery vehicles can be tuned to provide a specific rate and 
duration of release independently.  However, biodegradable matrices have been commonly 
observed to produce up to three distinct phases:  1) an Initial Phase (a.k.a. “Initial Burst”) that is 
typically categorized by the rapid delivery of drug upon hydration, 2) a “Lag Phase” marked by a 
near-zero rate of release for some period of time. and 3) a “Final Phase” where measurable 
release resumes, typically in a Fickian fashion.  Therefore, it would be useful to classify tools by 
their suitability for tuning the magnitude and/or duration of each individual phase in order to 
gain complete control over release.(Figure 2)  Further, by analyzing the attempts to control these 
fundamental system phenomena and documenting their effects on release behavior, a picture of 
formulation function can be developed. 
 
 
 
Figure 2: Tri-phasic release profile  
Diagram of the A) Initial Burst, B) Lag Phase and C) Final Release.  Note that any one of these phases may or may 
not be apparent depending upon the properties of the release system. 
8 
 
2.2 TUNING THE INITIAL BURST 
Numerous studies have addressed the “Initial Burst” and a summary of findings have been the 
focus of two reviews in the past decade
28,29
. Both of these reviews discuss hypothetical 
mechanisms of “burst” release and potential strategies for preventing or eliminating it.  
Maintaining the theme of this review, we will focus on the impact that individual “design tools” 
have on the magnitude and/or kinetics of the initial burst.  
2.2.1 Modifying burst magnitude 
The initial burst can easily encompass all of release or even be completely eliminated.  However, 
no one method exists for precisely targeting values across this entire range.  Instead, studies put 
forth a variety of techniques that change burst magnitude with varying degrees of sensitivity. 
2.2.1.1 Dispersion of Drug in the Polymer Matrix 
Several studies have succeeded in creating dramatic reductions in burst magnitude by forcing 
hydrophilic proteins to disperse in the hydrophobic polymer matrix.  For example, Fu et al 
eliminated the initial release of a water-soluble protein (human Glial-cell line derived 
neurotrophic factor) by using an ionic surfactant to dissolve the hydrophilic protein in-phase with 
the polymer
30
.  In contrast, an equivalent double emulsion formulation (with polymer entrapping 
pockets of aqueous protein) produced more than 70% initial release
30
.  A similar approach was 
adopted to eliminate the burst release of insulin using PEGylation, which aided the dissolution of 
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the protein in dichloromethane
31
.  Practically, partitioning experiments can be used to determine 
if other agents will dissolve/disperse in the same phase as the polymer (e.g. organic phase) with 
the aid of surfactants or other modifications
32
.  Since this design tool simply involves the 
dispersion of drug and polymer in a matrix, it should readily apply to any number of systems. 
Interestingly, less predictable results are observed when a cosolvent is used to stabilize 
hydrophilic drugs in the same phase as the hydrophobic polymer matrix
33,34
.  Using this approach 
on insulin-loaded PLGA microparticles reduced burst magnitude from 65 to 20%
34
.  However, 
when applied to another protein (granulocyte colony stimulating factor), this technique actually 
increased the magnitude of the initial burst
33
.  Yet both of these studies produce single emulsion 
systems by dissolving a protein in the co-solvent, dimethylsulfoxide, before mixing it with a 
polymer-dichloromethane solution.  It is unknown as to the source of the disparity, but it may be 
possible that this process may cause protein molecules to aggregate into a separate phase, giving 
rise to a measurable burst magnitude.  
2.2.1.2 Manipulation of Osmotic Pressure 
Subtle changes in burst magnitude have also been achieved by changing the osmotic 
pressure during the processing of systems that are intentionally fabricated with an internal 
aqueous phase (e.g. double (water-in-oil-in-water) emulsion systems, see Figure 1B).   
Accordingly, Jiang et al tuned the initial burst of bovine serum albumin (BSA) to values between 
30% and 80% of total release by adding salt or sucrose to the outermost aqueous phase during 
microparticle fabrication
35
.  The same technique has been used in other macromolecule-loaded 
systems to reduce the magnitude of the initial burst
17,36
.  Within each study, the reduction in burst 
magnitude was proportional to the amount of NaCl added to the outermost aqueous phase, (i.e. 
10 
 
the strength of the osmotic pressure gradient driving water out of the microparticles).  Because 
osmosis is a fundamental process, this design tool should extend to a wide range of contiguous 
systems, and is particularly important to account for in systems where the drug itself 
dramatically affects the osmotic pressure (such as plasmid DNA)
37,38
.  
2.2.1.3 Manipulation of Matrix Size 
A number of studies have also varied matrix size to tune the magnitude of burst release in double 
emulsion systems
2,6,36,39
.  While this property is particularly easy to tune during fabrication, its 
effectiveness at controlling the magnitude of initial release varies from agent to agent.  For 
example, initial release of the small molecule, lidocaine from polymeric microparticles dropped 
30% as particle size increased 10 fold
2
.  This trend is echoed over a larger size span by 
polyanhydride particles loaded with Butorphanol
39
.  However, the release of insulin was more 
sensitive to changes in particle size, dropping 35% in magnitude from just a 3 fold change in 
particle size
36
(Figure 3).   Limitations arise as matrix size is reduced to below 5μm because such 
small bodies are readily cleared in vivo by the reticuloendothelial system (RES, consisting of 
phagocytic cells like macrophages)
40
 or above 500µm in diameter as matrix hydration begins to 
affect the kinetics of the initial burst
41,42
.  However, for median sizes, this method presents an 
effective approach to tuning the magnitude of initial burst release.   
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Figure 3: Comparison of burst magnitudes from microparticles of varying size.   
Analysis was conducted on data from three different studies: Small molecule Lidocaine
2
, Insulin protein
5
 and 
Melittin peptide
6
. The burst magnitude of each system was affected to different extents by changes in matrix size. 
 
2.2.1.4 Manipulation of Drug Loading 
Discrete changes in initial burst magnitude have also been produced by altering the drug loading.  
Working with a variety of model proteins (lysozyme, carbonic anhydrase, alcohol 
dehydrogenase), Sandor et al noted that decreasing drug loading from 7 to 1wt% reduced the 
initial burst from a high of roughly 80% to just 15-40% of total release
43
.  Equally dramatic 
reductions in burst magnitude have been observed following changes in peptide loading
6,36
.  
Studies on small molecule release from polyester and polyanhydride implants have also reported 
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similar trends
44-48
.  Limitations to this technique do arise at low loadings (lower payload) or high 
loading (breakdown of matrix structure, e.g. percolation)
49
.  However, the simplicity and broad 
applicability of this tool still make it very attractive for inducing measurable changes to burst 
magnitude.  
2.2.2 Tuning the kinetics of the initial burst 
Methods for altering the rate (kinetics) of the initial burst may also prove useful if it can be 
manipulated to benefit the delivery strategy.  For example, rapid delivery of an antigen might be 
necessary for the successful function of a controlled release vaccine.  Alternatively, slowing the 
initial burst rate may bring the initial delivery of a prescription in line with its optimal, constant 
(zero order) release profile.   
2.2.2.1 Controlling Drug Dissolution Rate   
One way to influence burst release kinetics is to alter the encapsulated agent's dissolution rate.  
This has been accomplished by co-encapsulating an agent with a variety of excipients
50,51
.  
Experimenting with different clycodextrin excipients, Wang et al was able to tune the duration of 
initial release of beta-lapachone (a hydrophobic chemotherapeutic) to values between 1 week and 
1 day by complexing it with hydrophilic cyclodextrin of varying size
50
.  This approach to 
increasing burst rate should also apply to other hydrophobic, small molecules, that readily 
complex with cyclodextrin or other hydrophilic agents
29
.   
Interestingly, reports describing the use of excipients to decrease the rate of early release 
(rendering hydrophilic molecules more hydrophobic) are absent from the literature, possibly 
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because evidence suggests that these types of systems exhibit little to no initial burst
30
.  Further, 
a study intending to reduce dissolution rate by switching from amorphous to crystalline drug 
reported a similar change in burst magnitude, but not kinetics
52
.  However, studies comparing 
agents with different intrinsic dissolution rates have noted a correlation to burst kinetics in 
polyanhydride implants
53,54
.  This suggests that methods for reducing an agent's dissolution rate 
could slow its burst release.  However, until such methods are realized, excipients remain a 
reliable tool for increasing burst release rate of hydrophobic agents. 
2.2.2.2 Effect of Radial Drug Distribution 
A number of different fabrication methods have been used to control the radial distribution of 
drug within biodegradable polymer matrices, thereby altering their initial burst kinetics.  Such 
heterogeneous distributions have been achieved with double-walled microparticles which are 
formed by using multiple immiscible solvents to separate polymers of differing solubility into 
core and shell phases.  These systems consistently show reduced protein burst kinetics when the 
drug is trapped in the matrix core rather than when it is in the shell or loaded throughout
55,56
.  
Further, the extent of this reduction is proportional to the thickness of the shell separating the 
drug-loaded core from the outside environment
55
.  Coated implants (tablets, discs, or spheres) 
made from polyesters or polyanhydrides have produced similar results
57-60
.  Mixed results were 
observed in some small molecule loaded matrices, which could be explained by the preferential 
partitioning of such agents into the coating shell instead of the matrix core
61-64
.  Fortunately, 
studies have reported controlling the radial distribution of small molecules through an 
electrospray fabrication process
3,65,66
.  Piroxicam and Rhodamine loaded microparticles produced 
by this method showed significantly slower initial release kinetics when drug was concentrated 
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at the matrix core than when it was distributed closer the particle surface
3
.(Figure 4)  This 
technique was also recently applied to macromolecule loaded (Rhodamine-BSA or FITC-
dextran), double emulsion microparticles, but only the magnitude of the initial burst was 
altered
67
, as discussed in section 2.2.1.  Between electrospray fabricated microparticles and 
systems such as double-walled particles or implants, radial drug distribution can successfully 
modified for a diverse array of active agents.   
2.2.3 Initial burst summary 
A number of different techniques make it possible to tune the magnitude and duration of the 
initial release phase.  By altering processing methods, matrix size, osmotic pressure, or drug 
loading, the magnitude of the initial release can be tuned to nearly any value between 0 and 
100%.  By altering the agent dissolution rate or radial drug distribution, it is possible to tune 
kinetics of initial release as well.  Despite the encompassing applicability and diversity of these 
tools for tuning burst release, future research into mechanism of the bust and its relation to drug 
chemistry is needed to tune it a priori.   
2.3 TUNING THE LAG PHASE 
Following the initial burst, a lag (or pause in release) may occur before the remaining 
encapsulated drug is released.  By definition, this phase lacks measurable kinetics, but may 
possess significant duration.  However, particularly slow initial release or, conversely, early 
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onset of final release may serve to disguise this phase.  Hence, for the purposes of this chapter, 
the duration of the lag phase is defined as time elapsed prior to the onset of final release (day 0 to 
the resumption of drug delivery).    
2.3.1 Tools for tuning the duration of the lag phase  
2.3.1.1 Setting of Initial Polymer Molecular Weight  
Many studies have shown that the duration of the lag phase can be altered by varying the 
polymer's initial molecular weight (Mwo).  For example, Friess et al. induced a 10 day lag phase 
in gentamicin loaded microparticles by switching from a 13.5kDa PLGA to a higher molecular 
weight of 36.2kDa
68
. Comparable results have been reported for small molecule loaded polyester 
implants
69
.  This relation also holds true in peptide loaded microparticles
5,70,71
.  Macromolecule 
release data from different studies also confirms a clear trend between lag phase duration and the 
molecular weight of the PLGA matrix (Figure 5) 
5,30,35,43,72-78
. This fundamental trend is only 
preserved with a given class of agents, suggesting that the effect of polymer molecular weight is 
dependent, at least in part, upon some property (or properties) of the encapsulated agent
68,70,75
.   
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Figure 4: Relationship between polymer molecular weight and lag duration.   
Duration of the lag phase (squares) was determined by analyzing macromolecule release data from a number of 
different studies
5,30,35,43,72-78
.  The results fit a power expression (line).  
 
2.3.1.2  Controlling Polymer Degradation Rate 
Another well-documented tool that can be used to alter the duration of the lag phase is the 
polymer's degradation rate.  For copolymers, this is simply controlled by altering the ratio of the 
two monomers, with degradation rate typically being inversely proportional to hydrophobicity of 
the resulting polymer chain.  For example, in work by Cui et al where 9.5kDa 50:50 PLGA 
microparticles produced a melittin release profile with an 8 day lag phase, 10kDa 75:25 PLGA 
microparticles presented a 14 day lag phase
6
.  Similarly, Wang et al tested ethacrynic acid loaded 
films of 110kDa 50:50 PLGA and PLA, which produced lags of 1 or 6 days, respectively
79
.  This 
trend has also been echoed by polyanhydride copolymer microparticles loaded with BSA
80
, 
PLGA and PLA fibers loaded with BSA 
81
 as well as other polyester implants loaded with small 
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molecule drugs
82,83
.  The consistent performance of the polymer degradation rate and initial 
molecular weight as tools for controlling lag phase duration suggests that the two may act in 
concert via a common property such as polymer lifespan.   
2.3.1.3 Use of Catalytic Excipients 
 When a specific polymer chemistry or molecular weight is desired (and therefore not accessible 
as a tool to tune release), the degradation rate and, in turn, duration of the lag phase can also be 
modified by using an excipient.  This is evident in one study where proteinase K increased the 
degradation rate of PLA fibers eliminating all lag from the release of paclitaxel and 
doxorubicin
84
.  This enzyme will also catalyze the degradation of l-lactic linkages in PLGA 
copolymers and consequently should shorten the duration of lag phase in said systems as well
85
.  
An anhydride (acid) has also been used as a catalyst to hasten the degradation of poly-ortho-ester 
matrices, completely eliminating a 2-day lag phase
86
.  This mechanism should apply equally well 
to polyester or polyanhydride matrices whose hydrolysis is also affected by the presence of 
acid
41
.  Future work is needed to determine if acidic excipients will cause measurable damage to 
peptides or proteins. 
2.3.1.4 Post Fabrication Irradiation 
The duration of the lag phase can also be reduced by gamma irradiation
87,88
.  The most dramatic 
changes produced by this method were reported for the release of progesterone from PLA 
microspheres, where 100kGY of radiation reduced the lag duration from nearly 200 days (prior 
to exposure) to just 50 days 
88
.  Working with small molecule loaded PLGA microspheres, 
Fasiant et al also reported a short lag duration when 5-Fluorouracil loaded PLGA microparticles 
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were irradiated (4-33kGy)
87
.  These changes in lag duration can likely be attributed to the 
cleavage of polymer chains in the encapsulating matrix (e.g. reduction in initial polymer 
molecular weight), a phenomena whose effects are described earlier in this section.  
Interestingly, both studies also noted an increase in burst rate, a phenomena not observed with 
other degradation-based methods of altering the duration of the lag phase.  While this method for 
altering lag phase should apply to a wide range of polyester matrices, its utility may be limited 
because: 1) it simultaneously alters the kinetics of the initial burst, 2) it appears to be only 
capable of shortening the lag phase (not lengthening it) and 3) it may degrade sensitive agents 
such as peptides and proteins.   
2.3.2 Lag phase summary:   
Controlling the duration of the lag phase can be simply a matter of tuning the encapsulating 
polymer’s lifespan.  This can be accomplished by adjusting polymer initial molecular weight or 
degradation rate, as well as by using a catalytic excipient or gamma irradiation.  By carefully 
tuning the lag phase it is possible to either merge initial and final release into one seamless phase 
or separate them by considerable delay.  As lag phases were rarely observed in system releasing 
small molecules (< 300Da), further study is warranted to determine how best to induce and tune 
this phase in such systems.     
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2.4 FINAL RELEASE 
Control over the final release phase can help extend drug delivery or even determine how 
pronounced the effects of the initial burst and lag phase will be on the overall release profile.  
Because this phase is responsible for the delivery of the remainder of drug in the polymer matrix, 
its magnitude is (by definition) predetermined by the magnitudes of the prior release phases.  
However, the kinetics of this phase can still be readily tuned by several methods. 
2.4.1 Tuning the rate of final release 
2.4.1.1 Use of Polymer Blends 
Firstly, the rate of final release can be reduced (or its duration extended) by blending together 
like polymers
68,70,89-92
.  For example, by adding together equal measures of 36.2kDa PLGA and 
13.5kDa PLGA, Friess et al was able to extend the final release of gentamicin (small molecule) 
from just 3 days to 7 days
68
.  Similar mixtures have also been used to extended the release of 
peptides and proteins
70,90
. This tool has even been used to sustain protein (lysozyme) release 
from polyanhydride microspheres
92
.  Interestingly enough, this method of reducing the final 
release rate extends directly from methods for tuning the lag phase duration (which also marks 
the time until final release).  For instance, mixing together polymers with different lag phases 
could stagger the onset of final release, yielding an overall slower final release rate than either 
polymer could achieve alone.  Hence this technique for modulating the rate of final release 
should prove effective for any matrix system with an adjustable lag phase. 
20 
 
2.4.1.2 Control via Copolymer Ratio  
Data also suggests that duration of final release in polyester systems is dependent on the 
copolymer ratio of PLGA.  Studies on melittin release show that 50:50 PLGA microparticles 
complete final release in just 2 weeks, while comparable 75:25 PLGA microparticles take 3 
weeks to deliver nearly the same amount of drug
6
.  A similar observation can be made for the 
ethacrynic acid loaded films
79
.  (Note, in all aforementioned cases altering copolymer ratio also 
adjusted the duration of the lag phase via the polymer degradation rate, as described in section 
2.3.1)  While, this effect appears consistent across PLGA copolymers, further research is needed 
to better understand its mechanism and the breath of its applicability.  Tuning common factors 
such as polydispersity in the polymer molecular weight or semicrystallinity of the polymer 
matrix (which can lead to variance in the polymer lifespan
93
) may produce comparable effects in 
other polymer types
94
. 
2.4.2 Final release summary:  
A relatively limited number of techniques are able to alter the kinetics of the final release phase 
for a number of different systems.  Both blending like polymers and altering copolymer 
chemistry (for greater lactic content) decreases the rate of final release, allowing for more 
extended delivery.  Similarly reducing the polydispersity in polymer initial molecular weight or 
reducing the copolymer’s lactic acid content can increase the rate of final release.   
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2.5 CONCLUSIONS:   
Many methods for tuning the release kinetics of biodegradable polymer matrices have been 
tested in carefully designed experiments on a variety of different drugs.  The result is a set of 
independent methods for tuning the magnitude or kinetics of the initial burst, the duration of the 
lag phase and the rate of final release.  When used in combination, these design tools can 
produce release profiles ranging pure the Fickean diffusion to complex tri-phasic behaviors.  
Further progress can be made towards quantifying the changes in release produced by these tools 
with mathematical modeling. 
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3.0  DEVELOPING A PREDICTIVE MODEL OF RELEASE FROM BULK 
ERODING POLYMER MATRICES 
3.1 INTRODUCTION 
Spurred by a desire to hasten the development of new formulations, many efforts have been 
made to model degradation-controlled release profiles based on the physical properties of the 
matrix, drug, and polymer
4,95-101
.  The most notable of these models not only accurately describe 
release data, but also provide a means of predicting how to control it (i.e. predicting how changes 
in system properties will affect the release of a given drug).  This is an important distinction, as 
many models, through regression, will fit tri-phasic release data, while only predicting how one 
or two system properties will affect release.  As most system properties only alter a single aspect 
or phase of release kinetics, this would limit a model's ability to tailor release kinetics.  On the 
other end of the spectrum, when a model accounts for too many system properties, its utility for 
formulation design is limited by the number of properties that can actually be tuned during 
matrix fabrication.  Common ground for more specific characterization of mathematical models 
as design tools can be found in the phase or phases of release that they effectively be used to  
tune.  Compared on the basis of the phases that they describe, models can be evaluated for their 
accuracy, applicability to formulation design, and ease of implementation.   
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3.1.1 Evaluation of models addressing the initial burst by critical properties 
3.1.1.1 Agent Loading and Copolymer Ratio:  
Wong et al. modeled the initial burst release of Immunoglobulin G from PLGA microparticles 
with varying drug loading and copolymer composition
102
.  Analytical solutions to this diffusion-
dissolution model revealed a strong agreement to the first 50 days of release data when values for 
the agent diffusivity and dissolution rate constant were optimized to minimize sum-squared 
error.  The low variance in these optimized values may allow for the prediction of burst release 
in systems with different loadings or copolymer ratios.  (As some of the collected data was 
lacking a lag phase, at times, both of these properties appeared to impact the initial burst 
kinetics.)  Further work is required to determine if values for agent diffusivity and dissolution 
rate will have to be calculated anew when attempting to predict the burst kinetics of other 
proteins or polymer chemistries.   
3.1.1.2 Agent Loading, Solubility:   
Small molecule release from PLGA has been captured by a model that combines a Monte Carlo 
description of dissolution and erosion with partial differential equations describing pore-
mediated diffusion
100
.  This model was successfully applied to 5-fluorouracil release data from 
104kDa PLGA microspheres by optimizing values for mean polymer lifespan and agent 
diffusivity.  Importantly, values for loading, drug solubility and matrix size were specified for 
the given microparticle system instead of being computed by regression from release data.  This 
should allow the model to predict how changes in these system properties affect release, 
provided that their perturbation does not significantly alter the optimized values for mean 
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polymer lifespan and agent diffusivity.  While this predictive ability has yet to be tested, 
experimental studies suggest that altering the loading will affect the magnitude of the initial burst 
(section 2.2.1) and varying drug solubility will affect burst kinetics (section 2.2.2).  (In like 
systems, matrix size has been reported to affect the polymer degradation rate and, in turn, its 
lifespan, while having little impact on release kinetics
1
.)  Future implementation of this model on 
single emulsion systems (where agent solubility and loading have been experimentally varied) 
would promote its utility as a design tool.     
Zhang et al. have derived a detailed model for describing mono-, bi-, and tri-phasic 
protein release profiles
103
.  To account for this diversity in release behavior, this model actually 
contains three different versions of its core equations optimized to approximate a diverse range 
of experimentally observed erosion behavior.  Each version of the model's equations was tested 
on release data from systems with different erosion profiles.  By fitting the model first to mass 
loss (erosion) data, the most appropriate version of its equations was determined and values were 
computed for erosion rate constants.  Then release data was described by optimizing values for 
the initial tortuosity and dissolution rate constant.  Values for the remaining system properties 
(agent solubility limit, initial diffusivity, microparticle radius, drug loading, initial tortuosity and 
initial porosity) were taken from the literature.  Because sensitivity analysis shows that the 
erosion mechanism can have a dramatic effect on release kinetics, matrix-specific properties that 
are likely to affect erosion (e.g. microparticle radius, initial porosity or initial tortuosity) may 
prove a difficult means of precisely altering release.  Fortunately, this model still accounts for 
agent-specific system properties such as agent loading and solubility which can be used to tune 
the magnitude and kinetics of the initial burst, respectively (sections 2.2.1 and 2.2.2).  
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3.1.2 Evaluation of models addressing the burst and lag phases by critical properties 
3.1.2.1 Initial Polymer Molecular Weight, Irradiation:  
Diffusion-erosion equations have been combined with empirical correlations to predict the 
effects of post-fabrication, gamma irradiation on release
104
.  This model accurately fit bi-phasic 
release data from aclaribicin or progesterone-loaded, polyester PLA microparticles of varying 
molecular weight or irradiation exposure, respectively.  Optimized parameter values for agent 
diffusivity, degradation rate, lag-phase duration, erosion and auto-catalysis were successfully 
correlated to irradiation exposure. Based on these correlations a further regression-free prediction 
was made for a more heavily irradiated set of PLA microparticles.  This demonstrates that the 
model can successfully predict the experimentally observed effects of irradiation exposure on 
release, namely increased burst rate and decreased lag duration.  It is likely that similar 
predictions could be made for other agents and polyester matrix formulations if their system-
specific parameters (agent diffusivity, erosion half-life and degradation rate) are recalculated.  
With such adjustments, this model could aid in the prediction of initial burst kinetics and lag 
phase duration following irradiation exposure.  It is possible that equivalent correlations could be 
developed and used to predict the effects of varying initial polymer molecular weight as well.   
3.1.2.2 Polymer Initial Molecular Weight, Agent Distribution:  
Raman et al modeled the effects of polymer initial molecular weight and drug dispersion on 
piroxicam release from single emulsion microparticles
101
.  The model combines diffusion-
reaction expressions with a correlation relating piroxicam diffusivity to polymer molecular 
weight (D(Mw)) in order to predict release while only needing to optimize one constant (initial 
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drug diffusivity), which accounts for the kinetics of initial release.  Its descriptions of release 
were accurate for the initial burst and the lag phase, but deviated from the data as much as 15% 
at later points in time.  This likely occurred because the D(Mw) correlation requires extrapolation 
for polymer molecular weights less than 5kDa, an issue which could be resolved by gathering 
data from lower molecular weight polymer matrices.  As implemented, this model can predict 
changes in burst kinetics arising from drug distribution and changes in the lag phase duration due 
to polymer initial molecular weight. With an agent specific D(Mw) correlation and recalculated 
values for initial diffusivity in place, this model could be used to predict the performance of 
different drugs as well.    
3.1.3 Evaluation of models of triphasic release by their critical properties 
3.1.3.1 Microparticle Combinations:   
The aforementioned model of piroxicam release has recently been extended by Berchane et al 
with an algorithm for tuning release kinetics by mixing together different microparticle 
formulations at different ratios
105
.  This algorithm was used to optimize (using weighted sum 
squared error) the component mass fractions in a mixture of piroxicam loaded microparticles 
with different release behaviors to produce entirely new profiles, from linear to multi-phasic 
patterns.  This technique could readily be adapted to generating specific release profiles for any 
number of drugs provided that a library of formulations with suitably diverse release behaviors 
could be developed. 
27 
 
3.1.3.2 Erosion, Degradation, Drug Loading, Posority, Particle Size, Solubility, and 
Polymer Chemistry:  
Batycky et al modeled tri-phasic protein release by piecing together a number of analytical 
equations
4
. This model successfully predicted the release of glycoprotein 120 from PLGA 
microspheres based on measured values for 19 different parameters (Figure 5A).  Less rigorous 
predictions (using a number of estimated parameters) for tetanus toxin release captured the initial 
burst and lag phases but showed systematic deviations arising at just 15 to 45% of completion 
(Figure 5B).  This suggests that it is important to precisely measure or derive values for all model 
parameters if accurate predictions are to be made.  Eight of these parameters, such as effective 
drug diffusivity, rate of mesopore formation or burst release fraction, can only be determined 
through observation of the polymer matrix during in vitro degradation, erosion and release 
assays.  However, the remaining eleven parameters correspond to system properties that are 
commonly known or readily measured, namely microparticle radius, initial porosity (micro, 
meso, and occlusion), pore size distribution, polymer degradation rate, monomer molecular 
weights, soluble oligomer number, drug radius, drug molecular weight, and drug loading. 
Parametric sensitivity analysis, where each of these parameters is independently varied, will help 
determine which system properties specified in this model can be used to tune release
106
. 
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Figure 5: Protein release predictions for PLGA & PLA particles. 
A) Model's prediction (solid line) compares favorably with Glycoprotein release data (diamonds).  B) Estimations of 
tetanus toxin release (solid line) capture the initial burst and lag phase of the data from PLGA (crosses) and PLA 
(diamonds) microparticles.  Reproduced with permission of ref. 
4
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3.1.4 Summary of Mathematical Models:   
Each of the aforementioned models takes steps towards enabling the rational design of 
biodegradable controlled release matrices. In order to supplant the need for exploratory in vitro 
release experiments in the design of controlled release therapeutics, though, a model must satisfy 
three requirements. 1) The model must apply to a wide range of agents because each new 
therapeutic must deliver a unique drug
11,23
.  2) The release of such agents must be described 
entirely from readily attainable design parameters, thereby allowing researchers to acquire 
specifications for a matrix from a given release profile or dosing schedule
107
. 3) The model must 
be robust enough to capture the breadth of release behaviors that have been documented for the 
system in question, in this case, bulk eroding polymer matrices
5,6,30,43,68,70,72,73,79,80,108-111
.  
This chapter documents the development and implementation of a new controlled release 
model designed to meet the criteria specified above. This work was summarized in a manuscript 
by Rothstein et al. that was published in the Journal of Materials Chemistry in 2008{Rothstein 
2008}.  This model uses new methods to describe the release of water-soluble agents that are 
discretely encapsulated in bulk eroding, polymer matrices and that dissolve rapidly, relative to 
the time scale of release. In addition fundamental descriptions of release, the model includes two 
correlations that enable predictions with knowledge of just five parameters, all commonly known 
or easily measured prior to release. These parameters are microsphere radius Rp, occlusion radius 
Rocc, polymer degradation rate kCw, polymer initial molecular weight Mwo, and agent molecular 
weight MwA. As a test of the model, regression-free predictions were compared to multiple sets 
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of published experimental data. Furthermore, the range of attainable dosing schedules is explored 
by varying the matrix-specific parameters.   
3.2 MODEL DEVELOPMENT  
3.2.1 Release paradigm 
Consider an initially uniform matrix of known geometry comprised of a biodegradable polymer, 
such as a polyester or polyanhydride, and with randomly distributed entrapped release agent (e.g. 
drug of concentration CAo), loaded below its percolation threshold (such that agent remains 
discrete) to ensure matrix mediated release. This agent can either be dispersed as crystals (such 
as in the case of uniformly loaded systems, e.g. single emulsion-based particulates) or housed as 
a solution in occlusions (e.g. double emulsion-based particulates).
107
 At time zero, an aqueous 
reservoir begins to hydrate the matrix, a process which happens quickly for the bulk eroding 
polymers matrices considered herein
4,41
.  As the matrix hydrates, encapsulated agent adjacent to 
the matrix surface (with a direct pathway for egress) diffuses into the reservoir in a phase 
typically dubbed the initial burst  (Figure 6, phase 1). The relative size of the occlusion (Rocc) 
occupied by the encapsulated agent is proportional to the magnitude of the initial burst as 
illustrated in  Figure 7.  
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Figure 6: Schematic depiction of a paradigm that can account for four-phase release.  
A) Cross section diagrams depicting the four phases of release for a double emulsion microparticle with agent 
encapsulated heterogeneously in occlusions. Initially, agent abutting the matrix surface is released (1). The 
remaining agent requires the growth and coalescence of pores for further egress (2–4). B) Release profile for 
macromolecular drug encapsulated in biodegradable polymer matrix with four phases of release labeled. The 
numbers associated with each cross section diagram (A) indicate which phase of the release profile is illustrated. 
These phases are 1) initial burst, 2) lag phase, 3) secondary burst and 4) final release. 
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As the initial burst release commences, degradation of the polymer begins, increasing 
chain mobility and effectively leading to the formation of pores in the polymer matrix
32
 (Figure 
6, phase 2). Although a number of mechanisms have been proposed for this heterogeneous 
degradation profile, one hypothesis, which has been reinforced by experimental data, is based 
upon regions of varying amorphicity and crystallinity
93,112,113
.  It is believed that amorphous 
regions of polymer erode first, leaving behind pores (as shown using scanning electron 
microscopy)
1
. These pores appear to be essential for subsequent release
114
(Figure 6, phase 3). 
 
 Figure 7: Schematic depiction of the initial burst as it relates to occlusion size.  
A) The double emulsion particle contains large occlusions filled with drug solution and produces a significant initial 
burst. B) The more uniformly loaded (e.g. single emulsion particle, melt cast matrix) contains small granules of drug 
and has minimal initial release 
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With the cumulative growth and coalescence of these pores, agents are able to diffuse 
towards the surface of a polymer matrix that would otherwise be too dense to allow their 
passage
114
 (Figure 6, phase 4). Thus, a pore is defined as a region of polymer matrix with an 
average molecular weight low enough to allow the release of encapsulated agent. (This is in 
contrast to the occlusion, which is defined as a region occupied by dissolved or solid agent, 
marked by the absence of polymer matrix.) Further, the molecular weight associated with release 
may vary for each encapsulated agent type (small molecule, peptide, protein, etc.), leading to a 
size-dependent restriction for agent egress. 
With a size-dependent restriction on egress established, the degradation controlled release 
of any encapsulated agent can only occur when the following four conditions are satisfied. 1) 
The release agent must be present in the polymer matrix. 2) A pore must encompass the release 
agent. 3) That release agent must be able to diffuse through the encompassing pore. 4) The pore 
must grow and coalesce with others to create a pathway for diffusion to the surface. 
3.2.2 Model Equations 
Agent concentration within a matrix (such as a microsphere, rod, or thin film) can be calculated 
from Fick's second law (Equation 1) for any point in time (t) or space (r), provided that the agent 
is not generated or consumed in any reactions while within the matrix
96-98,100
.  
  
Aeff
A CD=
t
C



 (1) 
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Here Deff is an effective diffusivity term. Integrating CA/CAo over the entire matrix volume yields 
the cumulative fraction of agent retained in the matrix (P(t)) (Equation 2). 
For a sphere:   
P(t) = V
−1
CA/CAodV  (2) 
 
 
 
In turn, the cumulative fraction of agent released (R(t)), a metric commonly used to document 
formulation performance, is simply (Equation 3): 
  
R(t) = 1 − P(t)  (3) 
 
At the center point, line, or plane of the matrix (r = 0) symmetry conditions are defined such that 
dCA/dr = 0. At the matrix surface (r = Rp) perfect sink conditions are specified. (The impact of 
sink conditions has been explored in prior experimental work {Klose 2011}.)  A boundary also 
exists at a depth of Rocc in from the matrix surface (r = Rp − Rocc) where continuity conditions are 
defined. In the subdomain from Rp to Rp − Rocc (terminating one occlusion radius in from the 
particle surface), agent is subject to the initial release, such that Deff is simply a constant (D), 
reflecting the movement of agent through the hydrated occlusions abutting the matrix surface. In 
the subdomain from 0 to Rp − Rocc, agent is subject to pore-dependent release, such that Deff = D  
where D is the diffusivity of the agent through the porous matrix and is the matrix porosity. 
For a system of like matrices, such as microspheres or sections in a thin film, that degrade 
randomly and heterogeneously, the accessible matrix porosity is simply a function of time as a 
discrete pore has, on average, an equal probability of forming at any position in the polymer 
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matrix. Hence, the time until pore formation can be calculated from the degradation of the 
polymer matrix, as any differential volume containing a pore would have a lower average 
molecular weight than its initial value. Assuming that the polymer degradation rate is normally 
distributed,
112
 the induction time for pore formation will also follow a normal distribution. As 
this pore formation is cumulative, the time-dependent matrix porosity ( (t)) can be described 
with a cumulative normal distribution function (Equation 4). 
   (4) 
 
Here,  is the mean time for pore formation and 
2
 is the variance in time required to form pores. 
3.2.2.1 Pore induction time distribution  
Calculating the cumulative normal induction time distribution ( (t)) requires values for  and 
2
. 
For polymers that obey a first order degradation rate expression, the mean time for pore 
formation ( ) can be determined as follows: 
  
 
(5) 
where kCw is the average pseudo-first order degradation rate constant for the given polymer type, 
Mwo is the initial molecular weight of the polymer, and we define Mwr as the average polymer 
molecular weight in a differential volume of matrix that permits the diffusion of the encapsulated 
agent. For blended polymer matrices, the value for  was calculated by averaging the results 
obtained from equation 5 for each component.  
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It is reasonable to believe that the matrix molecular weight at release (Mwr), which 
dictates how much degradation is required before release can occur, would vary depending on 
the size of the encapsulated agent. Macromolecules or larger agents can only diffuse through a 
section of matrix if it is almost entirely free of insoluble polymer chains. Hence the Mwr for such 
agents is considered the polymer solubility molecular weight (668 Da for 50:50 PLGA as 
provided by Batycky et al.)
4
. As agent size decreases (as indicated by MwA), however, egress can 
occur through more intact sections of polymer matrix (higher Mwr), as less free space is needed to 
allow their passage. 
The distribution of polymer degradation rates (kCw(n)) attributed to matrix crystallinity is 
needed to calculate the variance (
2
) in the induction time distribution for pore formation 
( (t))
93
. To determine kCw(n), the first order degradation rate equation Mw = Mwoe
−kCw∙t
 was 
linearly fitted at three different time periods to published degradation data for the desired 
hydrolysable polymer. Fitting the initial slope of the degradation profile provides the degradation 
rate constant of amorphous polymer as degradation occurs faster in amorphous regions of the 
matrix
93
. Fitting data from the final weeks of degradation produces a rate constant for the 
crystalline material, as amorphous regions are largely eroded by this point. Finally, a fit of the 
entire degradation profile yielded a rate constant indicative of the overall morphology. 
With values for kCw(n) defined, a distribution of induction times ( (n)) was calculated 
using equation 5. For blended polymer matrices this (n) includes values calculated at all 
component kCw(n) and Mwo. The standard deviation was taken for (n), then divided by a 
crystallinity-based factor and squared, yielding an adjusted variance (
2
), which conforms with 
lamellar size data. 
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This crystallinity-based factor adjusts the probability of finding pores formed from the 
fastest degradation rate in kCw(n) to match the probability of finding a differential volume of 
matrix containing purely amorphous polymer. For all modeled cases, this differential volume is 
defined as a region large enough to allow the passage of a small virus or protein complex (20 nm 
diameter). As multiple lamellar stacks can fit into this differential volume, the probability that 
such a volume is purely amorphous can be calculated from of the number of stacks per 
differential volume and the average crystallinity of the matrix. From crystallinity data on 50 : 50 
PLGA matrices, 
93,112
 the probability of finding a purely amorphous differential volume is 
calculated as 0.05%. Thus, to ensure that the probability of finding a pore formed from the 
fastest degradation rate in kCw(n) also equals 0.05%, the standard deviation in the induction time 
distribution for pore formation was adjusted by a factor of 5. Similarly, factors of 4 and 2 were 
calculated from crystallinity data for 75:25 PLGA and polyanhydride matrices, 
respectively
112,115,116
.   Because each of these parameters is calculated from published x-ray 
diffraction crystallinity data, it provides a materials-based input (independent of encapsulated 
drug) for the model’s for solution  
3.2.3 Solution and Regression 
With values for and 
2
 selected (defining (t)), a finite element solution to equation 1 was 
calculated (Comsol®, v3.3) for the given matrix geometry, using default solver settings. (To 
decrease computation time, the matrix geometry was simplified to one dimension based on 
symmetry, for a sphere, or high aspect ratio, for a thin film.) The resulting concentration profiles 
were numerically integrated to calculate the cumulative fraction of agent released (equations 2 
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and 3). For validation, the numerical solutions of the model were fit to experimental data sets by 
varying Mwr and D. (It should be noted that data points charting the kinetics of the initial burst 
were omitted from these regressions, as the model only predicts the magnitude of this phase.) 
Each fit was optimized using the fminsearch function (Matlab®, R2007a), which minimized 
sum-squared error (SSE) or weighted sum-squared error (wSSE) when error bars were provided. 
3.2.4 Validation of math model 
As derived above, values for D and Mwr, while not easily quantifiable, are needed to solve the 
fundamental model equations 1–5. Hence, to further develop the model, regressions to multiple 
data sets were conducted to relate these parameters to more readily attainable system 
properties
5,6,30,43,68,70,72,73,79,80,108-111
.  For these regressions, values for the readily attainable model 
parameters, Mwo and Rp, were taken from the published data sets
5,6,30,43,68,70,72,73,79,80,108-111
.  
kCw(n) was calculated and averaged from several different sources
78,101,117-119
 as described above. 
Data points documenting the kinetics of the initial burst were not included for fitting, as the 
model, in its current form, only predicts the magnitude of this phase. (This current limitation is 
discussed further in Section 3.4.) Properties for the experimental systems described by these 
regressions are listed in Table 1.  Each fit to published data yielded optimized values for D and 
Mwr that were subsequently correlated to Mwo and Rp (Figure 8). 
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Table 1: List of experimental systems used for model validation 
Agent MwA/Da Polymer Mwo/kDa Rp/μm Ref. 
Metoclopramide 297 50:50 PLGA 98 75 
111
 
Ethacrynic acid 303 50:50 PLGA 110 35 (film) 
79
 
Betamethasone 392 50:50 PLGA 41.8 19.5 
110
 
Gentamicin 477 50:50 PLGA 13.5, 36.2 133, 276 
68
 
Leuprolide 1 209 50:50 PLGA 18, 30 20 
70
 
Melittin 2 860 50:50 PLGA 9.5 2.15, 3.5 
6
 
SPf66 4 700 50:50 PLGA 100 0.6 
109
 
Insulin 5 808 50:50 PLGA 6.6, 8 1.5 
5
 
Neurotrophic factor 12 000 50:50 PLGA 9.3 8.85 
30
 
BSA 69 000 PSA 37 10 
80
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Figure 8: Correlations for D and Mwr developed from regressions to experimental data in Table 1. 
A) Plot of polymer molecular weight at the onset of drug release (Mwr) vs. release agent molecular weight (MwA), 
(equation in insert). The data used to form this correlation comes from 50:50 PLGA systems. B) Plot of D versus Rp. 
The line indicates the power expression, D = 2.071 × 10
−19
 Rp
2.275
 which fits the estimations with an R
2
 = 0.95. 
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3.2.5 Regression-free predictions 
To test the model, regression-free predictions were made for a variety of biodegradable matrix 
systems, each with published controlled release data
6,68,80
. Values for the parameters needed to 
make these predictions were all taken from the literature
5,6,30,43,68,70,72,73,79,80,108-111
.  Values for 
kCw were kept consistent with values used in the validation optimizations, as these were 
assumed to depend wholly on polymer chain chemistry.  Values for Mwo, MwA, and Rp were 
taken directly from the published work under consideration.  The occlusion radius (Rocc) was 
found by averaging the sizes of 10 occlusions, randomly selected from scanning-electron or 
fluorescence microscopy images of the microspheres.  
The model's predictive capabilities were explored by specifying a priori conditions such 
as occlusion (Rocc) and matrix (Rp) sizes as well as the mean polymer molecular initial weight 
(Mwo) and its distribution. Specifically, occlusion size was varied from that of a matrix with a 
homogeneously loaded, small molecule (Rocc < 1 nm) to a larger occlusion containing drug (800 
nm), as could be found in double emulsion formulation, Rp was set between 8 and 150 μm and 
Mwo was varied from 7.4 to 100 kDa. In addition, blends of common polyesters were considered 
such as a 2:1 ratio of 7.4 kDa 50:50 PLGA and 60 kDa PLA or a 1:1 ratio of 10 kDa and 100 
kDa PLGA. To provide continuity all predictions were generated for a short peptide (900 Da) 
encapsulated in a spherical matrix.  
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3.3 MODELING RESULTS 
3.3.1 Validation 
Solving the fundamental model equations requires values for D and Mwr, which are difficult to 
directly measure. Fitting the model to release data for a wide range of agents generated values 
for molecular weight of release (Mwr) that display a strong correlation with agent molecular 
weight (MwA) as shown in Figure 8A.  Fitting a power expression (y = ax
b
) to the plot of the 
regressed diffusivity values versus particle size data (Rp), as suggested by Siepmann et al.,
1
 
resulted in a = 2.071 × 10
−19
 and b = 2.275 (R
2
 = 0.95) (Figure 8B). These correlations compile 
data from multiple agents, polymer molecular weights and matrix sizes (Table 1).  
3.3.2 Predictions 
3.3.2.1 Predictions of Release Data 
Regression-free model predictions for experimental data capture the magnitude of the initial 
burst, the duration of the lag phase, the onset of the secondary burst and the final release phase. 
Figure 9 displays one set of predictions for peptide release from various PLGA copolymer 
microspheres
6
. These predictions appear to extend to polymer matrices other than PLGA, such as 
polyanhydride microspheres (which, if sized less than 75 μm, are theorized to be entirely 
hydrated for the duration of release)
41
. The prediction for BSA release from 20:80 CPH:SA 
polyanhydride microspheres (Rp = 10 μm)
80
 illustrates this broader applicability ( Figure 10). In  
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Figure 9: Regression-free prediction for peptide release from PLGA microspheres.  
The Mwr for melittin (MwA = 2.86kDa) was calculated at 4.68kDa from the correlation in Figure 8. A) For the 9.5kDa 
50:50 PLGA microsphere (Rp = 3.7μm, Rocc = 0.52μm) D was correlated at 4.06 × 10
−18
m
2
/s. B) The D for 9.3kDa 
75:25 microspheres (Rp = 4.5μm, Rocc = 0.54μm) was calculated at 6.34 × 10
−18
 m
2
/s. 
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 Figure 10: Regression-free prediction for BSA release from polyanhydride microparticles. 
 System is composed of 20:80 CPH:SA polyanhydride (Mwo = 18 kDa, Rp = 10 μm and Rocc = 1.54 μm). As the Mwr 
values presented in Figure 8A are specific to PLGA copolymers, the Mwr for this prediction (940 Da) was acquired 
by fitting the model to data from microparticles fabricated in an identical manner using polysebacic acid (data not 
shown). In accordance with the correlation in Figure 8B, D was set at 3.67 × 10
−17
 m
2
/s. 
 
addition, release predictions have also been made for matrices formulated from a blend of two 
different polymers
68
 (Figure 11). All of these predictions serve to confirm that the model can 
describe: 1) the magnitude (but not the kinetics) of the initial burst from known occlusion size; 2) 
the duration of the lag phase from known polymer initial molecular weight, degradation rate and 
release agent molecular weight; 3) the onset of the initial burst from the matrix crystallinity 
derived rate distribution; and 4) the rate of subsequent release from the agent diffusivity (D) 
correlated to the matrix size.  
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Figure 11: Release predictions compared to in vitro data from blended PLGA polymer microspheres. 
Gentamicin was release from microspheres (Rp = 374.6 μm and Rocc = 24.7 μm) composed of a 1:1 blend of 13.5 and 
36.2 kDa 50:50 PLGA (asterisks). As the Rocc could not be determined from the published SEM images, the value of 
24.7 μm was acquired from different sized gentamicin-loaded microspheres fabricated under like conditions. The 
Mwr and D were correlated at 13.3 kDa and 1.48 × 10
−13
 m
2
/s, respectively. Bounds of the predictions reflect inherent 
error, propagated from variances in the model’s input parameters (dashed lines).    
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3.3.3 Theoretical Predictions 
By varying the readily attainable model parameters within physically relevant bounds for 
controlled release formulations, it was possible to predict behaviors ranging from a four phase 
release profile to zero order release (Figure 12). Changing the ratio of occlusion size (Rocc) to 
particle size (Rp) (representing the fraction of matrix volume defined as near the surface ) 
affected the magnitude of the initial burst ( Figure 7). The ratio of the polymer molecular weight 
at release (associated with the molecular weight of the release agent) to its initial molecular 
weight (Mwr/Mwo) and the mean reaction rate (associated with polymer type) were collectively 
found to be responsible for the duration of the lag phase. Lastly, modifying the distribution of 
degradation rates (kCw(n)) or incorporating an Mwo distribution (used to calculate the induction 
time distribution for pore growth) influenced the rate of onset for the secondary without affecting 
the initial burst. Tuning these parameters in combination can minimize the magnitude of the 
initial burst and the duration of the lag phase, while simultaneously slowing the rate of onset of 
the second burst, leading to a more linear release profile.  
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Figure 12: Theoretical release profiles for obtained by varying model parameters: Rp, Rocc, Mwo, kCw(n).  
The profiles progress from a typical four phase release pattern (solid) to zero order release (dotted). For the solid 
line a 13kDa 50:50 PLGA matrix was considered with Rp = 150μm, and Rocc = 23.5μm. The dashed line was 
generated based on a 1:1 blend of 10kDa and 100kDa 50:50 PLGA (Rp = 20μm, Rocc = 1μm). For the dotted line a 
2:1 ratio of 7.4kDa 50:50 PLGA and 60kDa PLA was considered in a single emulsion matrix with Rp = 8μm. 
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3.4 DISCUSSION 
In the effort to hasten the development of biodegradable matrix-based, controlled release 
therapeutics, many models have been developed to describe the release of specific classes of 
agents, such as small molecules or proteins
4,95,97-101
. In general, these models require parameters 
that can only be obtained by fitting controlled release data,
99,100
 or otherwise by carefully 
observing controlled release experiments
4
. In order to eliminate the need for exploratory in vitro 
experiments, which investigate the drug dosing schedules supplied by controlled release 
formulations, a model must be able to predict, without regression, a broad range of release 
behaviors for a wide array of agents, entirely from tunable matrix properties. To meet this goal, 
the model developed in the chapter includes new methods of calculating the magnitude of the 
initial burst release and the duration of the subsequent lag phase, which allow these features to be 
predicted with commonly known parameters regardless of the encapsulated agent type, be it 
small molecule, peptide or protein. This model was also applied to numerous sets of published 
data to generate values for two correlations. These correlations complete a set of readily 
attainable parameters for making regression-free predictions of drug release from uniformly 
hydrated biodegradable matrices. Finally, by varying the tunable parameters over rational 
bounds, the range of potential release behaviors attainable with such systems were explored. 
The comparison of model predictions and experimental data strongly suggests that the 
magnitude of the initial burst is directly proportional to the amount of agent localized to 
occlusions residing just inside the matrix surface. This region is defined over the entire surface of 
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the matrix to a depth of Rp − Rocc, such that any occlusion localized to this region would abut the 
matrix–reservoir interface. Prior models attributing the initial burst to the amount of agent 
adsorbed to the matrix surface required the fitting of empirical parameters for the 
absorption/desorption of each new drug type
4,95
. Further, results from several studies examining 
release from particles of uniform size and surface morphology, but varying occlusion size (based 
on the formulation method), suggest that it is unlikely that desorption from the surface (with 
surface area being proportional to the magnitude of the initial burst) is responsible for the initial 
burst phase of release
30,70
.  
Regression-free predictions of published experimental data also suggest that the model 
consistently calculates the duration of the lag phase for release agents ranging from small 
molecules to proteins. Prior models have only accurately predicted the duration of the lag phase 
for either small molecules
100,101,120
 or proteins
4
. The current model establishes a polymer 
molecular weight associated with release (Mwr) and inversely correlates it to agent molecular 
weight (MwA) (Figure 8A). The concept that small molecules can diffuse more readily through a 
higher molecular weight polymer matrix than larger molecules is supported by both diffusion 
flow cell studies
114
 and careful analysis of release data
5,6,30,43,68,70,72,73,79,80,108-111
.  In addition, 
scanning electron microscopy
1,119
 and other morphological
121
 studies have shown that with 
degradation, PLGA matrices become increasingly porous solids. The current model attributes 
this heterogeneous degradation to matrix crystallinity, a mechanism also supported by previous 
models
120,122
.  
The model predicts the onset of the secondary burst (Figure 6) using expressions that 
have both similarities and fundamental differences with those presented in the literature
4,95-101
. 
Like prior models, the current work employs Fick's second law with an Deff dependent on matrix 
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porosity. Saltzman and Langer first derived this expression to predict protein release from non-
degradable porous polymers
98
. Their lattice-based percolation calculations yield an accessible 
porosity that fits a cumulative normal distribution, a feature that our model is able to implement 
without estimated parameters. Recent controlled release models based on stochastic methods 
have also successfully employed a version of this equation to describe the egress of small 
molecules from regressed degradation rate constants
99,100
. The current work is, however, 
fundamentally different from these prior models
99,100
 as it describes pore formation in 
biodegradable matrices entirely from known parameters and applies to a broad range of agents, 
including small molecules, peptides, and proteins. 
As mentioned in section 3.3, the diffusivity values calculated for Figure 8B are consistent 
with those found in the literature
1,4,100,114
. These diffusivities display a power dependence on the 
size of the encapsulating matrix, where D = aRp
b
. This expression was originally developed by 
Siepmann et al.
1
 to compensate for the size-dependent increase in degradation rate that occurs in 
autocatalytic polymers such as PLGA
123
. Notably, this effect would be more realistically 
represented with a degradation rate expression that correctly accounts for the impact of size 
dependent autocatalysis on pore formation.  However, the present relation has proven very useful 
for the broad range of matrix sizes, polymer molecular weights, and agent types examined 
herein, even though it was originally developed for lidocane release from 45 kDa PLGA 
microspheres,
1
 (Figure 8B, Table 1). The diffusivity coefficients ranging from 10
−14
 to 10
−16
 m
2
/s 
calculated in prior models also support this finding
98,100
. Our regression-free predictions (Figure 
10–12) help to confirm that this power expression will relate D to matrix size for many different 
polymers with an acid-based, autocatalytic, first-order rate expressions, including both 
polyesters
124
 and polyanhydrides
118
.  
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Even though the mathematical framework presented herein provides broader applicability 
than prior models,
4,95,97-101
 it still requires several assumptions. Specifically, the model considers 
a water soluble agent that dissolves rapidly, relative to the duration of release, and that is loaded 
discretely in a bulk eroding, biodegradable polymer matrix. Efforts are currently under way to 
relax these assumptions in order to describe more complicated systems. For instance, we 
speculate that systems exhibiting slower kinetics during the initial burst may be subject to 
dissolution effects. Other efforts will focus on replacing the correlation of D to Rp with a 
physically relevant degradation rate expression that inherently accounts for size dependent 
autocatalysis to provide greater accuracy when examining matrices with extreme sizes (<100 nm 
or >1 mm). Furthermore, simple diffusion reaction equations can be added to the current model 
framework, extending its predictive capabilities to slowly hydrating or surface eroding systems, 
such as large polyanhydride implants. However, even prior to these additions, the model still 
predicts published data on agent egress from bulk eroding biodegradable matrices (Figure 10–
12), which can provide a range of release profiles (Figure 12). 
Finally, having confirmed the model's predictive capabilities, the range of release 
behaviors that can potentially be attained from bulk eroding matrices were explored. Predictions 
for such matrices cover a continuum of behaviors ranging from abrupt burst–lag–burst profiles to 
sustained linear release (Figure 12). These profiles satisfy the dosing schedules for numerous 
therapeutic applications, such as the constant delivery of a chemotherapy agent or the replication 
of multiple vaccine doses with a single injection
11,125
.  Along with (1) the model's applicability to 
a wide array of agents and (2) its use of physically relevant parameters, its ability to capture a 
broad range of release behaviors (3) completes the set of three specifications required for any 
framework that supports a rational design methodology. 
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3.5 CONCLUSIONS 
A simple, deterministic model was developed for the prediction of release for hydrophilic, agents 
encapsulated in bulk eroding biodegradable polymer matrices. Model development required 
application of diffusion-reaction mathematics and the development of two new correlations in 
order to extend predictive capabilities to the broad range of agents investigated.  Further, 
regression-free predictions from this model provide strong support for the alternative 
explanations developed to account for the magnitude of the initial burst and the duration of the 
lag phase. The current diffusion-reaction-correlation framework can also be expanded to cover 
poorly-soluble drugs, polymer types, and device geometries, including centimeter scale matrix 
implants, which are all affected by matrix hydration. 
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4.0  MATHEMATICS FOR HYDRATION LIMITED SYSTEMS 
4.1 INTRODUCTION 
The bulk eroding polymer systems discussed in Chapter 3.0  do not typically deliver drug at a 
constant rate, the release behavior required for the safe delivery of most prescription 
medications.  For this reason, scientists developed surface eroding drug delivery matrices whose 
degradation and erosion behavior naturally produce sustained release.  Surface eroding systems, 
as their name suggests, erode preferentially from the surface inward.  This behavior is a function 
of polymer hydrolysis rate, which is much higher than in bulk eroding systems, and their 
millimeter/centimeter scale sizing.  The rapid consumption of water by hydrolysis and the large 
volume of water required to fill the matrix (mm
3
 vs µm
3
) work to keep water out of the bulk of 
the polymer matrix.  This limits the processes of drug dissolution and pore formation, which 
mediate diffusive release, to the surface of the polymer matrix.    
The gradual formation of pores in or erosion of the matrix surface is thought to be the 
rate limiting step in release from systems, such as polyanhydride implants.  Theoretical 
descriptions of this process are found in most models of surface eroding systems.
15-17
 Of note is 
work by Gopferich et al on the development of a stochastic model of surface erosion that has 
been featured in several articles examining controlled release of different small molecules.
15, 18-21
  
Similar models of surface erosion have also been developed using non-stochastic approaches, 
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although these models have only been tested on select sets of mass loss or small molecule release 
data.
16, 17
     
Recent data by Burkersroda et al reveals that systems which begin drug release under 
surface erosion most likely transition to a bulk eroding mechanism as mass is lost from the 
surface and the matrix size shrinks (i.e. the characteristic length scale of diffusion decreases) 
22
.  
The matrix size at this transition from surface to bulk erosion has been dubbed the “critical 
length”.  Conversely, this critical length can also be viewed as the distance water can penetrate 
into a matrix before it is entirely consumed by hydrolysis.  Calculations using an average 
degradation rate and initial molecular weight placed this length at 75µm for polyanhydrides
22
, 
which suggests that many implants made from these polymers will undergo a transition from 
surface to bulk erosion while release is still occurring.  
This chapter describes the first model suitable for predicting a broad array of release 
behaviors from surface eroding matrices that transition from surface erosion to bulk erosion 
during the course of their lifespans.  This work was summarized in a manuscript by Rothstein et 
al. that was published by the journal Biomaterials in 2009
126
.  This model builds off of the model 
in Chapter 3.0 that focused on predicting release for a wide array of agents from bulk eroding 
systems
12
.  Specifically, the current model combines diffusion/reaction equations, which account 
for the system’s hydration kinetics, along with sequential descriptions of dissolution and pore 
formation to compute drug release.  Further, all parameters required to solve these equations can 
be obtained prior to controlled release experiments, allowing predictions to be made without 
regression.  In support of prior work reporting empirically obtained critical lengths 
22
, the 
diffusion/reaction equations employed by the current model are used to compute this 
characteristic parameter from rate expressions
23.  To test the model’s accuracy, regression-free 
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predictions were compared with published controlled release data from several different 
polyanhydride and poly(ortho-ester) implants.   
4.2 METHODS 
4.2.1 Release Paradigm 
Consider a hydrolysable polymer matrix loaded with a finite amount of release agent or drug.  
This agent is randomly dispersed throughout the matrix in a powdered or crystalline form.  
Further the agent is loaded discretely (below its percolation threshold), occupying either small 
granules or larger occlusions, as dictated by the matrix fabrication method.  These occlusions or 
granules are distributed randomly throughout the polymer matrix, such that the probability of 
finding drug at any point in the polymer matrix is constant at all positions within the matrix.
12
  
At time zero, water or buffer begins to hydrate the matrix.  Specifically, water diffuses 
into the matrix and is simultaneously consumed through the hydrolysis of the polymer matrix 
22
.  
Hence, a larger matrix with a faster hydrolysis rate, such as a polyanhydride implant, will have a 
sharper concentration gradient of water than a smaller matrix (microsphere) or one with a less 
labile polymer, such as a poly(lactic-co-glycolic) acid.   
Following the hydration of a region of matrix, release of drug can be limited by its 
solubility or dissolution kinetics. The dissolution rate expression for this process depends upon 
the agent’s solubility and concentration15 as well as the concentration of solvent.  If an agent is 
highly soluble in water, dissolution may happen on a time scale that is much shorter than the 
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duration of release.  In systems where hydrophobic molecules have been encapsulated, however, 
dissolution can occur over a considerable amount of time, dramatically affecting the release 
profile.
15, 24
  
After an agent has dissolved, its diffusive egress may be further restricted by the 
encapsulating matrix.   In this case, the matrix needs to degrade to the point where a network of 
pores is formed, permitting egress of encapsulated agent
12, 25
.  This degradation is assumed to 
happen randomly and heterogeneously throughout hydrated regions of the matrix.  Further, the 
degradation of the matrix occurs in tandem with the dissolution of the agent, and both are 
dependent upon the hydration kinetics of the system.  The interplay between these factors can be 
translated into a framework of coupled equations for describing release.  
4.2.2 Model Development 
The time and space-dependent concentration profile of water within a hydrolysable polymer 
matrix of initial molecular weight (Mwo) can be calculated from competing diffusion-reaction 
equations.  As water diffuses into a matrix, a process described by Fick’s second law, it is also 
consumed in hydrolysis of the polymer matrix, (written below as a second order reaction, which 
applies to polyesters and polyanhydrides
8, 26
).  Hence, equation 1 below describes the presence of 
water within the polymer matrix. 
MwkCCD=
t
C
wWW
W 


  (1) 
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Where CW is the time and space dependent concentration of water, DW is the diffusivity of water 
in the polymer matrix (found to be on the order of 10
-12
 m
2
/s for a broad array of systems 
22
), k is 
the degradation rate constant, and Mw is the polymer molecular weight.   
As part of the hydrolysis reaction, polymer bonds are also broken leading to a decrease in 
the molecular weight of the polymer matrix. The kinetics of this process can be described by the 
standard second order rate expression commonly used for both polyesters and polyanhydrides.
8, 
26
  (Equation 2) 
MwkC=
t
Mw
w


 (2) 
It is assumed that components of the polymer matrix (e.g. initially high molecular weight 
polymer degradation products) do not diffuse considerably before the onset of erosion (Mw ≈ 4 
kDa), by which time the release of most types of agents will have commenced. In line with 
previous models, a “degradation front” can be defined at a point in the polymer matrix where the 
gradient of the polymer molecular weight (dMw/dr vs. r) is at a minimum
19, 27
.  This minimum is 
defined as the inflection point of the continuous function, Mw(r), such that the initial average 
molecular weight at this front is ½ Mwo, provided that the core of polymer matrix is still at its 
initial molecular weight.   
With the hydration kinetics defined, the dissolution of the drug can be calculated, which 
is normally done with a second order rate expression.
28
  Unlike the standard systems used to 
derive this second order expression, the solvent concentration of the present system varies with 
position and time, and hence must be considered as well.  The standard expression is also written 
in terms of the solute surface area and mass transfer coefficient which have been translated into 
equivalent, readily measurable parameters.(Equation 3) 
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WnAnSndis
S CCCk=
t
C



 (3) 
where kdis is the intrinsic dissolution rate constant, CSn, is the normalized concentration of solid 
drug in the polymer matrix, CAn is the difference between the aqueous agent concentration and its 
maximum solubility (CAmx), normalized by CAmx, and CWn is the normalized concentration of 
water.  Boolean expressions were used to ensure that CSn, CAn, and C\Wn were bounded by 0 to 1, 
ensuring a physically relevant model solution.  Next, the position-(r) and time- (t) dependent 
concentration of dissolved agent in a polymer matrix can be calculated from Fick’s second law 
and the dissolution rate expression. (Equation 4)   
WnAnSndisAeff
A CCCk+CD=
t
C



     (4) 
where Deff is an effective diffusivity term.  Integrating the total normalized concentration of 
agent in the matrix over all space yields the cumulative fraction of agent remaining in the matrix 
at each point in time (Equation 5) 
dV
C
C+C
V=P(t)
So
AS1

       (5) 
dr
RL
r
C
C+C
=P(t)
PSo
AS




2
2
 (For a rod or disc) 
And the cumulative fraction of agent release (R(t)) is:  (Equation 6)   
 P(t)-1 = R(t)        (6) 
As in Chapter 3.0  the Deff term in Equation 4 is dependent on the matrix porosity (ε) and the 
diffusivity of the agent through the porous matrix (DA).  However, in the hydration-limited 
systems covered by this model, porosity is time- and space-dependent and is therefore based 
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directly on the molecular weight of the polymer instead of degradation time as done in Chapter 
3.0 . (Equation 7) 















 
 1
2σ2
1
1
2
+
MwMw
erf=ε r      (7) 
This means that the molecular weight of the polymer matrix during release (Mwr) is used directly 
in the porosity expression.  Changes are also made in the calculation of agent diffusivity (DA), 
which correlated directly to matrix size for bulk eroding systems.  For a surface eroding matrix, 
autocatalytic degradation only occurs in the region of matrix that is hydrated, thus the system’s 
critical length is used to determine the diffusivity from the correlation in Figure 8.   
The boundary conditions for the polymer phase, as well as the aqueous and solid release 
agent phases, match those defined in a prior model for bulk eroding matrices
12
.  Briefly, 
symmetry conditions (dCn/dr = 0) are defined at the matrix center and perfect sink conditions 
(Cn = 0) are set at the matrix surface (at radius Rp and length L in a cylinder or disk).  For water 
concentration, the same internal symmetry conditions still apply, but the concentration of water 
at the matrix surface is set to match that of an infinite reservoir, with a concentration of Cwo 
calculated as the density of water over its molecular weight.  Further, when the encapsulated 
agent is gathered in large occlusions or pockets (relative to the size of the entire matrix), such as 
would be found in a double emulsion fabricated microsphere, the matrix should be represented 
with two sub-domains, as demonstrated previously,
12
 to account for the resulting initial burst.   
4.2.2.1 Limiting Cases 
Depending on the nature of the encapsulated agent, it may be possible to simplify the 
mathematical description of release.  If an agent possesses a high aqueous solubility and 
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dissolves rapidly, such that the rate of dissolution is at least 2 orders of magnitude faster than the 
rate of diffusion, the timescale of dissolution is negligible.  When modeling such cases,
30-32
 the 
drug was assumed to dissolve instantaneously in water.  Hence, Equation 3 can be neglected 
entirely and Equation 4 can be simplified to the following form. (Equation 8) 
Aeff
A CD=
t
C



        (8) 
where CAo becomes the initial concentration of agent.  In total, these simplifications reduced the 
model to three sets of diffusion-reaction equations instead of four and eliminated three input 
parameters (CSo, kdis, and CAmx).   
Alternatively if an agent has a Mwr > Mwo, by definition, it can diffuse freely through the 
newly hydrated polymer matrix and does not require degradation of the matrix for egress.  
Specifically, the agent is small enough to pass freely through the matrix and, as such, pores 
formed during degradation are no longer needed to provide a pathway for diffusive egress; hence 
Deff = DA. In this case the expression for matrix porosity (Equation 7) can be neglected.   
 
4.2.3 Model Implementation 
By adopting the proven approach to calculating release as detailed in section 3.2.5, existing 
correlations
12
 can be used along with the model to generate regression-free predictions. To 
calculate such predictions, the model was coded in Matlab® (Mathworks, r2007a) and computed 
using the finite element method on Comsol® (v3.1).   Meshing was successively refined, until 
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node-density independent results were observed.  Otherwise, default solver settings were 
maintained.   
4.2.3.1 Critical length 
To investigate the effects of polymer molecular weight (Mwo) and degradation rate (k) on the 
transition from surface to bulk erosion, only equations 1 and 2 were considered.  This transition 
occurs at a set matrix size, dubbed the critical length.
22
  Burkersroda et al originally defined the 
critical length as the distance water can travel through a matrix before the rate of diffusion equals 
the rate of degradation, such that in a surface eroding system, the rate of degradation surpasses 
the rate of diffusion.
22
  However, when mathematically accounting for these two rates with 
Fick’s second law and a second order rate expression (applicable to autocatalytic hydrolysable 
polymers) this original definition becomes physically untenable because the Cw term in the 
hydrolysis rate expression prevents the reaction rate from ever surpassing the diffusion rate.  
Thus, in order to determine the erosion mechanism of the matrices examined herein, we defined 
critical length as the matrix size where the polymer residing in the degradation front hydrolyzes 
at its most rapid rate, as noted by a minimum in ∂Mwf /∂t vs. t.  In other words, during surface 
erosion, this front moves progressively inward, slowing its traverse only as the matrix begins to 
uniformly hydrate.   With the onset of bulk erosion, the hydrolysis reaction taking place 
throughout the matrix can no longer consume the water before it penetrates to the matrix core.  
This leads to a matrix where the water concentration is at a maximum and the polymer molecular 
weight has not significantly decreased from its initial value. Together, these conditions maximize 
the degradation rate (-kCwMw), resulting in the fastest possible drop in the average polymer 
molecular weight.  Hence, it can be said that the matrix size, where degradation proceeds (on 
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average) at its fastest average rate, denotes the end of surface erosion and the onset of bulk 
erosion, and therefore can be defined as the critical length.   
Using this definition, the critical length was calculated for a variety of polymers, 
including PLA, PLGA, PFAD:SA, and PSA, at initial molecular weights ranging from 5kDa to 
130kDa.  The results of these calculations were used to determine if published release data 
1, 30, 32
 
was generated by surface eroding, bulk eroding, or transitioning phenomena.  Specific 
calculations were also performed to check the erosion mechanism of matrices used in other 
modeling literature.
20, 31
   
 
4.2.4 Release Predictions 
The simplified forms of the model described in section 4.2.2.1 were validated against release 
data from matrices that could be represented in 2-dimensions using axial symmetry.  Values for 
common model parameters Rp, L (for a cylinder), Mwo, MwA, CWo, CSo, CAmx, k, Dw, and kdis were 
specified directly from, or calculated using parameters specified in, the materials and methods 
sections of published literature 
30-33
.  The correlations developed in Chapter 3.0 were used to 
calculate values for DA and Mwr.  
It is important to note that the poly(ortho-ester) matrices investigated herein are unique in 
the field of controlled release because they contain a small molecule anhydride excipient.  This is 
proposed to alter the degradation mechanism of the polymer by increasing the rate of 
autocatalysis in the system.
34
   Fortunately, data on the hydrolysis of this anhydride excipient 
was published for these matrices and was used to enhance model caculations.
31
 Specifically, this 
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data was used to calculate the amount of water diverted from polymer degradation into anhydride 
hydrolysis as a function of time. The newly calculated rate expression was amended to the 
hydrolysis reactions to adjust for the additional consumption of water by the excipient.   
4.3 RESULTS 
4.3.1 Matrix degradation kinetics 
Solutions to equations 1 and 2 generate hydration and degradation profiles for a specified 
polymer matrix.   Figure 13 shows degradation profiles (Mw/Mwo as a function of r and t) for 
matrices composed of a single polymer where the dominate erosion mechanism has clearly been 
predetermined by carefully selecting the matrix size.  In a system undergoing surface erosion, the 
degradation-erosion front will move inward toward the center of the matrix as both degradation 
and erosion are confined to the periphery ( Figure 13A).  In bulk eroding systems, in which 
degradation occurs randomly throughout the matrix, the matrix size remains constant as its 
average molecular weight decreases ( Figure 13C).  This change in average molecular weight 
begins at the most rapid rate possible, with water concentration and polymer initial molecular 
weight both being at maximal values, and decreases as the number of hydrolysable bonds is 
depleted.  Hence, average degradation rate in the polymer matrix should be at a maximum with 
the onset of bulk erosion (or in other words, during a transition from surface to bulk erosion) 
(Figure 14A).  In turn, the critical length is calculated as the matrix size (marked at the center of 
the degradation front) when this transition occurs.  Increasing the polymer degradation rate, 
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indicating a more labile hydrolysable bond type, correspondingly decreases the critical length, 
indicating more dominate surface eroding behavior.  Likewise, increasing the polymer initial 
molecular weight also decreases the critical length (Figure 14B).   
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 Figure 13:  Degradation profiles (Mw relative to Mwo as a function of distance and time) for various spherical 
matrices of 10kDa PSA. 
 Matrix size is varied (X axis) to explore the various erosion schemes: A) surface erosion, B) a transition from 
surface to bulk erosion and C) bulk erosion.  The lifetime of each matrix changes with its size, such that each line in 
A) represents 1 month, B) represents 1 day and C) represents 2 hours.    In each figure, the line furthest to the right 
and top indicates the earliest time point.  
B)
C)
A) 
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Figure 14:  Calculation of critical length  
Calculations used a 2
nd
 order rate expression as a function of both the initial molecular weight of polymer and 
hydrolysis rate constant.  A) Critical length (point 2) was calculated as the matrix size (dashed line) in which the 
average molecular weight of polymer at the degradation front (solid line) decreases most rapidly (point 1), indicating 
the onset of bulk erosion.  B) Values for critical length as a function of initial molecular weight for a variety of 
polymer matrices: PLA (diamond), 50:50 PLGA (square), 50:50 PFAD:SA (triangle) and PSA (circle).  Linear 
interpolations have been added between data points of the same set to aid in interpretation 
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Having determined the matrix specifications required to maintain surface erosion, the 
model’s ability to predict controlled release from matrices with a variety of different erosion 
mechanisms was examined.  Further, systems with different hypothesized, release rate-limiting 
steps were also examined.  The tested systems range from bupivacaine release from FAD:SA 
polyanhydride disks (dissolution limited, bulk eroding), to gentamicin release from FAD:SA 
polyanhydride rods (degradation limited, surface eroding), to amaranth release from POE disks 
(degradation limited, surface and bulk eroding).
30-32
  
4.3.2 Dissolution controlled release 
Work by Park et al.
30
 examines the release of a small molecule, bupivacaine, from a 50:50 
FAD:SA polyanhydride disk with a 4 mm radius and 1 mm thickness sized at slightly below the 
calculated critical length for this system  (~1.7mm).  This suggests that the system would exhibit 
bulk eroding behavior and, as such, model predictions made with and without taking into account 
the hydration kinetics should both match the bupivacaine release data with comparable accuracy 
( Figure 15).  In line with this result, both predictions follow the trend set by the in vitro data with 
the prediction from the surface erosion model producing a slightly more accurate result than the 
simplified version of the model that neglected hydration kinetics.  As error in the measurement 
of in vitro release is cumulative greater deviation between model predictions and experimental 
data is expected at later time points.  It was also hypothesized that dissolution kinetics were an 
important factor in determining the release rate of bupivacaine and failing to consider them 
increased the SSE by a factor of 25 (SSE = 4.9004, data not shown).  
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 Figure 15: Predictions of dissolution-controlled, release of drug.   
The experimental data (asterisks) was generated from polyanhydride disks releasing the sparingly soluble 
agent, bupivacaine. 
30 
Model predictions were generated without regression while considering surface eros ion 
(solid, SSE = 0.0204), and assuming bulk erosion (dashed, SSE = 0.0691). To make these regression -free 
predictions, system-specific parameters were set as follows:  Rp = 4mm, L = 1mm, Mwo = 50kDa, CSo = 
288.42mol/m
3
 and CAmx = 2.184mol/m
3 
kdis = 0.046mol/m
3
s.  D was calculated as 4.61x10
-12
m
2
/s from a 
correlation published previously.
12
 Model solutions were computed at times corresponding to each 
experimental data point. 
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4.3.3 Degradation controlled release 
Stephens et al 
32
 documented gentamicin release from a 35.8kDa Mwo 50:50 FAD:SA 
polyanhydride bead with a 4mm diameter and a 12mm length, a matrix on the same order of 
magnitude as, but still slightly larger than the calculated critical length of 1.9mm.  Based on the 
calculations of critical length presented in Figure 14B and the those made by Burkersroda et 
al.,
22
 this system should exhibit surface eroding behavior, and any attempt to accurately model it 
should account for hydration kinetics.
22
  If a prediction for release is made without accounting 
for hydration kinetics, as detailed in
12
, a relatively poor fit to the data is observed (SSE = 
0.4350).  However, when accounting for hydration kinetics, using equations 1 and 2, the model’s 
prediction improved dramatically (as expected), resulting in an SSE of 0.0657 (Figure 16).   
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Figure 16: Predictions for degradation-controlled release of drug.   
The experimental data (asterisks) charts gentamicin release from FAD:SA matrix rods.
32
 Model predictions were 
generated without regression while considering surface erosion (solid, SSE = 0.0657) and assuming bulk erosion 
(dashed, SSE = 0.4350). To generate these regression-free predictions, the following values were used: Rp = 2mm, 
L = 12mm, Mwo = 35.8kDa, Mwr = 13.3kDa, DA = 5.94x10-12m
2
/s.  Model solutions were computed at times 
corresponding to each experimental data point and linearly interpolated. 
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Work by Joshi et al examined amaranth dye release from POE disks (10mm diameter, 
1.4mm thick), which had their erosion mechanism controlled by the addition of phthalic 
anhydride.  When a low amount of anhydride (0.25w/w%) was present in the disk, a bulk 
eroding mechanism was postulated to dominate, a point confirmed by our own critical length 
calculations (data not shown).  In contrast, with the addition of just 1% anhydride excipient, the 
critical length dropped to 684µm, a value slightly below the shortest matrix dimension, 
suggesting that surface erosion should dominate (at least at early times).
31
 Predictions of drug 
release from both of these systems take into account both the increase degradation rate from and 
the consumption of water by the anhydride excipient.  Because these predictions were only 
computed at experimentally measured time points and linearly interpolated, abrupt changes in 
the rate of release seem to occur.  Predictions made without considering the presence of 
anhydride increased error is observed in the predictions (data not shown).  Accounting for these 
effects significantly improved prediction for both the 0.25% anhydride matrix, reducing error by 
a factor of 4, and the 1% anhydride matrix, reducing error by a factor of 6, when compared to 
previously published results.
31
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Figure 17:   Predictions of release from (A) bulk eroding and (B) surface eroding POE matrices.   
Predictions have been made for the experimental data for dye release (astricks), while accounting for the hydrolysis 
of the anhydride excipient, with the complete model (solid line, (A) SSE = 0.0237 and (B) SSE = 1.1539) and the 
simplified version which assumes bulk erosion (dashed line, (A) SSE = 1.0077 and (B) SSE = 0.0061).  For 
calculations in both A and B, the following parameters were used:  Mwo =  28.2kDa, Mwr = 10.2kDa, Rp = 5mm, 
and L = 1.4mm.  Based on their differing anhydride contents, values of DA were unique to A and B, with DA = 1.44 
x 10
-12
 m
2
/s in A and DA = 9.75 x 10
-12
 m
2
/s in B. 
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4.4 DISCUSSION 
Biodegradable matrices for controlled release have been traditionally classified as either surface 
or bulk eroding and mathematical models of drug delivery from these systems have often 
reflected this classification in their assumptions.
7-10
  Recent data suggests that many surface 
eroding systems actually transition to a bulk eroding mechanism while drug release is 
occurring.
22
  With this in mind, a new model was developed to predict drug release from 
matrices undergoing multiple different erosion schemes, the first of its kind to describe the 
release of a wide array of agents without regression.  This model uses diffusion-reaction 
equations to describe the hydration kinetics, drug dissolution and degradation controlled release.  
Using the equations governing matrix hydration, a mechanistically accurate method for 
calculating a system’s critical length was developed, and then applied to a range of common 
systems.  Regression-free predictions (which use parameters that can be obtained prior to release 
experimentation) were made including and (for validation purposes) ignoring the effects of 
matrix hydration in both smaller and larger than their respective critical lengths.  Specifically, the 
model has been used here to predict bupivacaine release from polyanhydride disks
30
 and 
gentamicin release from polyanhydride cylinders
32
 as well as amaranth red release from 
poly(ortho-ester) disks
31.   The model’s applicability is not, as shown previously, limited to small 
molecules and should apply with comparable accuracy to systems that encapsulate and release 
macromolecules.
12
   
Several of the fundamental concepts from the current model’s paradigm have been 
separately employed in prior models.
12-17
  However, the equations used to translate these 
concepts into mathematical predictions for drug release have, however, been altered in some way 
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from their previous forms.  For example, a dissolution rate expression has been used in prior 
published work.
15
  Unlike this previously published expression
15
, the form in equations 3 and 4 
include a term for the dimensionless concentration of water that accounts for potential solubility 
limitations associated with partially hydrated systems.  Another example comes from the 
porosity expression, which has been translated from a time-dependent form that assumes a 
uniform degradation rate 
12
 to a version with broader applicability, based on the local molecular 
weight of the polymer matrix.  Finally, the concept of using diffusion/reaction equations to create 
a model that uniformly captures different erosion schemes has also been investigated before.  
One prior model based on species-dependent, diffusion/reaction equations was successfully 
developed and applied to data for dye release from POE disks (Figure 17). This model made 
predictions using system-specific parameters that could not be directly measured.  In contrast the 
model derived in this Chapter uses a far simpler diffusion-reaction description of release that still 
provides comparable predictive power.  This is confirmed by regression-free predictions of the 
amaranth red release data made with a greater degree accuracy (i.e. lower error in the prediction 
of data) that with prior models.
31
   
An examination of hydration and degradation profiles based on Equations 1 and 2 show 
that the model derived in this Chapter can produce profiles that resemble surface erosion, bulk 
erosion and the transition between the two based on a careful selection of matrix size.  Further, 
these degradation profiles ( Figure 13A, B) provide a direct means for calculating a theoretical 
critical length (i.e. where a given polymer transitions from surface to bulk erosion) (Figure 14). 
In contrast to the original calculations of critical length, which used an Erlang distribution to 
represent the degradation rate,
22
 this new calculation relies on a second order rate expression that 
can directly account for radial gradients in polymer molecular weight within the matrix.  When 
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accounting for the different degradation rates used in these two expressions, both sets of 
calculated values for critical length agree within order of magnitude for all systems tested.     
Comparison of predictions from the model to experimental data from biodegradable 
matrices serves to validate elements of its release paradigm.  The bupivacaine-loaded disks 
modeled in  Figure 15 showcase the importance of the dissolution and hydration rate expressions 
in generating accurate (SSE = 0.0172)  predictions for the release of a sparingly soluble agent 
from a polyanhydride matrix.
30
 ( Figure 15)  Attempting to predict the release of bupivacaine 
without considering its slow dissolution produced inaccurate predictions.  Conversely, 
predictions made without considering the system’s hydration kinetics show only a slight decrease 
in model accuracy.  Prima facie, it may be surprising that a slight drop in accuracy is observed 
with this system which, being a bulk eroding system, is most often characterized by rapid, 
uniform hydration.
11
  However, prior work indicates that, while bulk eroding systems in the 
micron size-range hydrate in minutes, bulk eroding implants (as defined by diffusion rate > 
degradation rate) on the order of millimeters can take days to become uniformly hydrated.
13
  
When such an implant only delivers drug over several days or weeks, this longer hydration time 
can significantly delay release, even though the system can be technically considered “bulk 
eroding”.  
Regression-free predictions for the POE matrix (Figure 17A) provide a different view for 
the importance of accounting for various mechanisms of matrix dynamics and physical agent 
egress.  Like the bupivacaine-loaded matrix featured in  Figure 15, predictions for this system 
were also significantly better when hydration kinetics were accounted for by the model.  This 
provides additional support for the conclusion that hydration kinetics can significantly influence 
the rate of drug release from bulk eroding implants.  Unlike dissolution-limited release of 
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bupivacaine, though, the readily-soluble amaranth red being released from this system is thought 
to only be restricted by the POE matrix.  This system contained an anhydride excipient which 
had to be accounted for in the model’s description of matrix degradation. 31  Attempting to 
predict release from this system without accounting for the diversion of water into the hydrolysis 
of the anhydride led to increased error during day 1 to 3, when the anhydride excipient is 
postulated to be hydrolyzing.
31
 (data not shown)  Even with this increased error, predictions from 
the current model still offer an improvement in accuracy (lower SSE) over prior modeling 
work.[31]   
The implants examined in Figure 16 are slightly larger than the calculated critical length, 
and gentamicin is large enough to be readily restricted by the polymer matrix, making this a 
prime example of how release occurs in a system that transitions from surface to bulk erosion.
32
  
Support of the model paradigm for release from a transitioning system is found in the accurate 
regression-free prediction (SSE = 0.0821) data from this system
32
 (Figure 16).   Failing to 
consider matrix hydration kinetics greatly (8-fold) decreases the accuracy of this prediction, as 
would be expected for a system that begins under surface erosion.  This change is much more 
dramatic than the one observed for comparable bulk eroding systems (e.g.  Figure 15), which 
provides a perspective on the crucial that role hydration kinetics play in systems that transition 
from surface to bulk erosion.  
With respects to the POE controlled release data in Figure 17, it is apparent that the 
simplified form of the model, assuming bulk erosion, generates a more accurate prediction of the 
amaranth red release data from the disk with 1% anhydride content than the full version of the 
model, even though the matrix should theoretically begin release under a surface eroding 
mechanism. However it is important to note that published empirical evidence, from time-lapse 
77 
 
images of matrix cross-sections, clearly shows a distinct change in internal morphology, between 
5 and 8 hours of incubation, that suggests water has already perfused into the matrix core.
35
  This 
hydration appears to occur much more rapidly than is predicted by equations 1 and 2 (data not 
shown).  During the time period between 5 and 8 hours, the initially rapid, average hydrolysis 
rate also transitions to a near zero value
31
, which is inconsistent with published predictions based 
on random chain scission theory.
31
  Taken together, this evidence suggests that another process, 
beyond the diffusion/reaction kinetics considered herein, causes water to perfuse the matrix 
earlier than expected by simple diffusion and hydrolysis for this system.   It is possible that the 
unaccounted driving force could come from an increase in matrix osmotic pressure, brought 
about by the 1w/w% of anhydride excipient.
36
  Regardless, this data serves an example of how 
actual phenomena can create situations with dynamics that extend beyond model assumptions.  
However, once the correct physical phenomenon has been determined (using cross sectional 
analysis here), the model will accurately predict release if constrained accordingly. 
Together, the validations performed on published release data sets (Figures 16-18) 
confirm that the regression-free predictions appear accurate when the systems in question 
conform to the model’s fundamental assumptions.  System attributes, such as high loading 
(above the percolation threshold) or the presence of excipients, can cause the experimental data 
to deviate from model predictions. Future work could further expand the applicability of the 
model developed herein with addition of equations accounting for such phenomenon such as 
system osmotic pressure or drug percolation.   
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4.5 CONCLUSIONS 
A new model for predicting release from surface eroding biodegradable matrices has been 
developed.  This model attributes egress to matrix hydration, agent dissolution, and polymer 
degradation instead of relying on the traditional assumption that release is solely erosion 
controlled.  Further, accounting for matrix hydration with diffusion/reaction equations captures 
the transition from surface to bulk erosion in common polymer systems. Strong agreement with 
multiple published data sets supports future use of the model as a design tool, allowing 
researchers to rapidly acquire the matrix specifications that will yield a desired release profile.   
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5.0   IMPACT OF PREDICTIVE MATHEMATICAL MODELS ON IN VITRO 
CONTROLLED RELEASE ASSAYS 
5.1 INTRODUCTION 
One direct application of the models developed in Chapters 3.0 and 4.0  is to collection and 
interpretation of in vitro release data.  This drug release data is generated by simply suspending 
and incubating microparticles in buffer at body temperature over time.  Ideally this data provides 
a cost-effective means of gauging if a formulation’s release kinetics will be suitable for a given 
application.  However, interpreting in vitro data or, moreover, designing a study to efficiently 
capture unambiguous data can be non-trivial.   As discussed in prior Chapters, a formulation's 
rate of drug release can fluctuate dramatically over the course of an assay (Figure 2), often in 
ways that are difficult to intuit.  Incorrectly timing the collection of release data can mask key 
fluctuations in release rate or even make it appear that release is in fact complete when it is not.    
The challenges faced in gathering and interpreting the data generated by in vitro release 
assays are similar to those encountered in analysis of pharmacokinetic (PK) data.  Like in vitro 
release assays, the data collected in PK studies provides evidence of drug concentration only at 
discrete points in time.  However, in PK studies today, it is now standard to employ proven 
mathematical models that allow researchers to accurately interpolate and extrapolate upon 
collected data
127
.  This type of analysis is essential for the accurate computation of important PK 
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processes adsorption, distribution, metabolism and excretion
33
.  If comparable model-driven 
analysis were regularly applied to in vitro release data as well, then key performance parameters 
such as the rate and duration of release could be determined for incomplete or sparse data sets.  
Further, model predictions could permit sample points to be optimally timed in subsequent in 
vitro or in vivo assays if these parameters need to be validated more fully.  Such analysis would 
be particularly valuable when designing formulations of PLGA, whose patterns of release drug 
are often difficult to anticipate
95
.   
Accordingly, this chapter will demonstrate how a mathematical model can be used to 
retrospectively evaluate existing sets of release data in order to generate additional insight into 
the formulations’ release behaviors.  Specifically, data sets for evaluation were selected to 
illustrate common issues, like lack of closure or widely spaced sampling times, that make their 
results difficult to definitively interpret.  The mathematical model from Chapter 3.0 will be used 
for this evaluation because its validated covered system similar to those considered herein
126,128
.  
When appropriate, additional in vitro release assays were also carried-out to validate sets of 
interpolative and extrapolative model predictions.  Overall, these mathematical evaluations of in 
vitro release data have the potential to yield useful information about formulation performance 
and insight that can guide the design of futures studies. The contents of this chapter have been 
summarized in an article title “A Retrospective Mathematical Analysis of Controlled Release 
Design and Experimentation” accepted for publication in Molecular Pharmaceutics.   
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Poly(lactic-co-glycolic)acid (PLGA) RG502 (Mwo ≈ 9kDa) was purchased from Boehringer 
Ingelheim (Ingelheim, Germany).  Enfuvirtide (T-20) was obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH from Roche.  Nitro oleic acid 
(NO2-OA) was composed by an equal mixture of 10-NO2-octadec-9-enoic acid and 9-NO2-
octadec-10-enoic acid and synthesized as previously described
129
. Solvents, assay reagents, and 
other chemicals were purchased from Thermo Fisher Scientific (Waltham, MA). 
5.2.2 Microparticle fabrication 
Microparticles were prepared using the emulsion processing technique as described
52
. Briefly, 
200 mg RG502 PLGA was dissolved in 4 ml dichloromethane (oil phase). One hundred μl of an 
agent stock solution (either 2mg/ml enfuvitide in 2.4mg/ml sodium carbonate solution or 1mM 
NO2-OA in methanol) was added to oil phase, which was then mixed for 10s using a probe 
sonicator (Sonics and Materials Inc., Danbury, CT).  This mixture was then homogenized at 
2,300 rpm for 1 minute in 60ml of 2% PVA (MW ∼ 25,000, 98% hydrolyzed) solution, using a 
homogenizer (Silverson L4RT-A). This emulsion was immediately poured into 80 ml of 1% 
PVA solution, and dichloromethane was allowed to evaporate. After 3 hours, the particles were 
centrifuged (1500g, 10 min, 4°C) and washed x4 in deionized water.  Microparticles were then 
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re-suspended in 5 ml of deionized water, frozen on dry ice and lyophilized (Virtis Benchtop K 
freeze dryer, Gardiner, NY; operating at 60mTorr). 
5.2.3 Microparticle characterization 
Microparticles were sized using the volume impedance method with a minimum of 10,000 
measurements on a Beckman Coulter Counter (Multisizer 3). Microparticle surface morphology 
and shape were examined using a scanning electron microscope (JEOL JSM-6330F, Peabody, 
MA).  The loading of the enfuvirtide microparticles was measured by dissolving 5mg of 
microparticles in 250 ul dimethylsulfoxide (DMSO).  Peptide was then extracted with the 
addition of 1 ml of 0.05M NaOH / 5% sodium dodecyl sulfate (SDS) and measured using the 
microBCA assay.   The loading of NO2-OA could not be measured by this method as the 
presence of SDS interfered with the detection of this agent.  
5.2.4 In vitro release assay 
Release data was measured accumulatively, as done previously
52
.  A known amount of 
microparticles was suspended in 500ul of phosphate buffered saline (DPBS, pH 7.4, GIBCO, 
Invitrogen) and placed on an end-to-end rotator at 37
o
C.   At regular intervals the microparticle 
suspensions were centrifuged, allowing the supernatant to be collected and particles to be 
resuspended in an equal volume of DPBS.   
Enfuvirtide concentration in the supernatant was detected either by microBCA or high 
pressure liquid chromatography (HPLC).  The microBCA assay was carried out using 
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Spectramax M5 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA) as detailed 
in the manufacturer’s protocol (Pierce, Thermo Fischer).  For HPLC, detection was carried out as 
done previously
130
. A Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific, Waltham, 
MA)  was used with a XTerra RP18 5µm 3.0x15mm column (Waters Corporation, Milford, MA) 
and enfuvirtide was detected on a Dionex RF2000 fluorescence detector (ex = 280nm, em = 
350nm).  Solvents and gradients were kept consistent with previous work, yielding peaks for 
enfuvirtide at 4.86min and insulin (internal standard) at 2.6min.   
NO2-OA concentration was quantified using high-performance liquid chromatography-
electrospray ionization mass spectrometry (HPLC-ESI MS/MS) as previously reported
129,131
. 
Briefly, the released NO2-OA was chromatographically resolved using a 20 × 2-mm cartridge 
column (Mercury MS Gemini 3μm C18, 110 Å, Phenomenex, Torrance, CA) with a flow rate of 
0.75 ml/min using a water (A)/acetonitrile (B) solvent system containing 0.1 % acetic acid. A 
linear gradient of B from 11 to 100% was developed in 3.5 min and used to separate the ions, 
followed by their detection on a triple quadrupole mass spectrometer (API 5000, Applied 
Biosystems/MDS Sciex, Framingham, MA) using the specific 326.3/46 and 344.3/46 transitions 
for NO2-OA and 
13
C18-NO2-OA respectively.  For quantification, peak areas of NO2-OA and 
13
C18-NO2-OA were calculated using Analyst 1.4.2 quantification software (Applied 
Biosystems/MDS Sciex, Thornhill, Ontario, Canada), and the ratio of analyte to internal standard 
was calculated to determine the concentration.  
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5.2.5 Collection of published release data 
Published data was collected from the figures of manuscripts using Plot Digitizer software (v. 
2.4.1), as done previously
126,128
.   Release profiles in these figures were enlarged to a size of 600 
by 400 pixels allowing accurate measurement of the scales on their axes.   Data points were then 
manually targeted, yielding a numerical coordinate for each point.  All sets of published release 
data collected were assayed accumulatively, by measuring the concentration of drug or protein 
released into the media.   
5.2.6 Model predictions 
All mathematical predictions of controlled release were made using the model developed by 
Rothstein et al., as done previously
128
.  This model was coded in MATLAB(v7.12) and solved 
using the finite element method with COMSOL(v3.5a).  To initialize solutions, values for the 
drug's molecular weight (MwA), the polymer's initial molecular weight (Mwo) and the 
microparticle radius (RP) were assigned based on the published materials and methods of each 
system considered.  The value for occlusion size (Rocc) was calculated from SEM images of the 
microparticle internal morphology, when available, and otherwise was back-calculated from the 
average magnitude of the given system's initial burst as derived previously
128
. As Rocc only 
contributes to the prediction of initial burst magnitude, this back-calculation does not interfere 
with the model’s predictions regarding the timing or rate of the secondary burst, which are of 
primary focus in this work.  The polymer degradation rate (kCw) was held constant for each 
copolymer ratio as follows: 50:50 PLGA, kCw = 0.08636day
-1
; 75:25 PLGA, kCw = 0.0342day
-1
; 
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and PLA, kCw = 0.0169day
-1
.  With these input parameters, the model could then predict the 
given system’s release profile.  The results were then plotted against the respective set of 
experimental data for statistical analysis. 
As the mathematical model used currently does not account for kinetics of the initial 
burst (only the magnitude
128
), data points within the first 72 hours of release were omitted from 
this statistical analysis. The accuracy of mathematical predictions was quantified by the 
normalized residual squared error (nRSS = residual sum of squares divided by the number of 
data points compared) and used as a metric of prediction accuracy instead. For the results section 
on widely spaced data points, equivalent calculations were made to quantify the prediction’s 
deviation from linearity with a specified gap between two data points (nRSSi).  Both of these 
metrics, unlike the r
2
, do not unduly weight values near the mean.   
5.3 RESULTS 
Evaluation of published data reveals two major areas of opportunity where in silico predictions 
may be able to better inform the design and validation of degradable controlled release 
formulations.  First, if data is collected infrequently enough to produce a jump in cumulative 
release, the duration and kinetics of release can be difficult to resolve and an in silico prediction 
can help interpolate between widely spaced data points.   Second, release studies may also (for 
any number of reasons) be terminated prior to the completion of release, leaving subsequent 
kinetics undocumented and perhaps even leaving the impression that the partially documented 
profile is complete.  In this case, in silico predictions can be used to extrapolate upon the existing 
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release data. Both of these areas of opportunity are illustrated in more detail with the following 
examples:  
5.3.1 Interpolation of release data sets with widely spaced sample points 
A number of data sets include intervals in sampling that result in low resolution of the release 
profile. This can occur for a number of reasons, including an expectation that release will follow 
a different pattern, unavailability of the researcher for empirical sampling, or concern that more 
closely spaced intervals would not allow for enough drug release to permit detection. However, 
when data sampling is too infrequent, important changes in the rate of drug delivery may be 
difficult to identify.  This was the case when enfuvirtide release was measured from PLGA 
microparticles at 10 day intervals (Figure 18A).  The low sampling rate was selected to ensure 
detection of enfuvirtide, a therapeutic peptide, by the micro BCA (µBCA) protein assay, which 
had a detection limit of 980 ng/ml.  The resulting gaps in data accounting for 33 and 44% of drug 
release leave open many interpratations (broken lines, Figure 18A), which can be clarified by the 
model’s prediction (solid lines, Figure 18A).  Subsequently, release from these microparticles 
was measured using high pressure liquid chromatography (HPLC) which has a detection limit 
below 39.1ng/ml for enfuvirtide, despite being less cost and time efficient.  This detection 
method allowed enfuvirtide release to be measured every 1 to 2 days, filling in the gaps left by 
the prior study (Figure 18B) in order to validate any conclusions made through model 
predictions.  The resulting HPLC-detected release profile closely follows the profile predicted by 
the earlier mathematical analysis, providing strong evidence that the interpolation based on 
model predictions accurately describes the actual enfuvirtide release behavior.  
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Figure 18:  Testing model predictions for the interpolation of in vitro release data from enfuvirtide loaded 
9kDa 50:50 PLGA, 20µm particles.   
A) Initial release measurements using the µBCA assay with widely spaced intervals (triangles).  Broken lines are 
provided to illustrate the range of possible alternate interpretations that could be made for the release profile based 
on the standard error. An interpolative prediction was made using the mathematical model which would suggest that 
actual release profile (solid line). B) Release measurements made by highly sensitive HPLC experiments at short 
intervals confirms the accuracy of the interpolative prediction (circles). (nRSS = 0.0030)  
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As with our data, the literature includes a number of release data with significant gaps 
between sample points.  For instance, in one assay of lysozyme release, over 40% of the drug is 
delivered during a 28 day window where no data was collected (Figure 19A)
43
.  As a result, the 
timing of the transition from first burst to second burst is unclear and could follow any number 
of patterns within the range marked by green curves.  In this specific case, mathematical analysis 
of this data suggests that release is predicted to continue in a sustained manner between data 
points without a more prominent burst of drug with possible upper and lower bounds at 30 (or 
alternatively) 50 days (Figure 19B).  Importantly, the variation between this prediction and ideal 
linearity (a point-to-point interpolation in the gap; nRSSi = 3.0E-4) is similar to what is 
calculated as the overall model deviation from all other experimental data points (nRSS = 3.8E-
4).  In another study, superoxide dismutase release was measured at 6 points over 60 days 
(Figure 20A)
77
.  Because these sample points were spaced unevenly, significant gaps occur from 
days 3 to 29 and days 38 to 50, accounting for 15% and 40% of release, respectively.  This 
leaves the data open to a range of interpretations (indicated by green shading) including the 
possibility that release proceeds linearly over the 60 days (Figure 20A, broken line).  However, 
in this specific case, the model prediction suggests that release is not sustained for the duration of 
60 days.  In contrast, a lag-burst pattern is predicted through the first gap where little release is 
occurs between days 3 and 20, followed by rapid release from day 20 onward(Figure 20B).   
During this window (days 3 to 29), the prediction’s deviation from point-by-point linear 
interpolation (nRSSi1 = 1.27E-2) far exceeds the error inherent in the model’s prediction (nRSS 
= 4.7E-3; nRSSi1 > nRSS), suggesting that the predicted deviation from linearity in the gap is 
indeed statistically much greater than the collective deviation from other data points.  In the 
second gap (days 38 to 50), the prediction’s deviation from linearity (nRSSi2 = 4.9E-3) is 
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actually comparable to the error inherent in the model’s prediction (nRSSi2 ≈ nRSS), suggesting 
that no significant change in release rate is expected to occur during this gap.   
 
Figure 19: Evaluations of in vitro data for lysozyme encapsulated in 12kDa 50:50 PLGA
17
.  
A) In vitro release data points (circles) jump from 18% at day 28 to 66% by day 56, leaving a range of potential 
interpretations as to the formulation’s release kinetics (shaded area).  B) Mathematical results predict a specific a 
release profile for this formulation (line).  
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Figure 20: Evaluations of in vitro data for superoxide dismutase (SOD) 
SOD was encapsulated in 40-70kDa 50:50 PLGA microparticles (14µm)
18
.  A) Gaps in this data (circles) suggest 
that SOD release could proceed in a sustained, linear fashion (dotted line) following the initial burst.  B) 
Mathematical results indicate a non-linear release profile for this formulation (line).  
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Significant gaps also appear in release data from PLGA microparticles loaded with model 
enzymes
43
, hormone antagonists
70,132
, and anti-inflammatory agents
133
, among others
39,68
 (release 
behavior not shown, but summary statistics are included in Table 2).  In some cases, 
retrospective analysis predicts that release will not deviate from a sustained or linear manner 
during the gap between data points
39,132,133
 (Table 2, nRSSi < nRSS or nRSSi ≈ nRSS)70,133. 
However, in other cases significant changes in release rate occur during gaps (Table 1, nRSSi > 
nRSS)
43,68,70
.    
Table 2: Interpolative Predictions 
Encapsulated Rp Rocc Mwo kCw MwA Gap Size 
Overall 
Error 
Linear  
Error  Ref 
Agent (µm) (µm) (kDa) (day
-1
) (Da) (Day, %) (nRSS) (nRSSi) 
 
Carbonic 
anhydrase 0.533 0.205 12 0.08636 68900 28 45 0.0020 0.0246
  17 
Leuprolide 20 1.8 10 0.08636 1210 7 43 0.0014 0.0021
  19a 
Octreotide 10.5 0.525 28 0.08636 1020 7 45 0.0025 0.0029
  19b 
Dexamethasone 5.5 2.86 70 0.08636 392 13 37 0.0061 0.0061
 20  
Gentamicin 276 69 36.2 0.08636 477 8 45 0.0012 0.0030 
 21a 
Butorphanol 200 40 29.7 0.3278 327 1 44 0.0062 0.0035
  21b 
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5.3.2 Extrapolation of release data sets that terminate prior to completion 
Many sets of release data document only one burst when additional release would be 
expected
42,95,128
.  This is not surprising given that the additional release, often in the form of a 
secondary burst, may only occur after weeks, months or years, while of the most functional 
assays or animal models using these formulations require just days or weeks to complete. Indeed, 
our studies on the novel anti-inflammatory agent, NO2-OA, began with a single batch of particles 
and 1 week release assay to confirm that this novel agent could be encapsulated and delivered 
intact from microparticles (Figure 21A).  Specifications for this formulation, including size, 
polymer molecular weight, and internal matrix morphology were measured, and used to initialize 
a model prediction that extrapolates beyond the range of the preliminary data (Figure 21B).  In 
order to test the accuracy of this prediction, the preliminary formulation was reproduced and 
assayed in triplicate for the full predicted duration of its release profile, with a sampling 
frequency selected to capture key changes in the rate of release This second assay confirmed that 
the formulation’s release profile closely follows the model prediction (Figure 21C).   Notably, 
our initial release curve only captured less than 25% of the total release behavior, which was 
captured by the model prediction.  
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Figure 21: Testing an extrapolative prediction 
A) Data from preliminary in vitro assay of NO2-OA release from 9kDa 50:50 PLGA 20µm particles.  B) Predicted 
release behavior for the same formulation. C)  Release from formulations produced in triplicate closely followed the 
model prediction. (nSSR = 0.0020) 
 
C) 
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Like this prior example, the literature includes a number of examples where release assays are, 
for whatever reason, terminated prior to closure.  Indeed, one set of PLA microparticles loaded 
with the protein superoxide dismutase (SOD) was assayed for 50 days without showing 
additional release beyond the initial burst.  However, predictions indicate that SOD release will 
only reach completion in an additional 200 days (Figure 22)
77
.  Importantly, this will result in 
 
 
 
  
Figure 22: Extrapolated SOD release from 106kDa poly(lactide) microparticles.   
In vitro data (circles) only documents 60% of release
18
.  The 40% of encapsulated protein remaining is predicted to 
release between days 150 and 250. 
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release of 40% of the encapsulated drug following day 150 if this formulation were placed in 
vivo and not removed before this time.  In another study, recombinant human Growth Hormone 
(rhGH) release was measured for 28 days, recording delivery of 78% of the anticipated 
payload
134
. Mathematical predictions show that release, which appears to asymptote, actually 
began a secondary burst on day 20 (Figure 23).  This burst continues until day 40, whereas no 
additional information is provided past day 30 by the assay.  Predictions were also evaluated for 
data sets from PLA and PLGA formulations loaded with many other proteins, peptides and small 
molecules
72,84,90,135-138
  (Table 3).   For a number of these systems, the release is predicted to 
continue for more than 2 months beyond the end of in vitro data collection
90,137,138
.    
Figure 23: Release of rhGH from 45kDa 50:50 PLGA microparticles.  
In vitro data (circles) was only collected for 28 days
22
.  In silico predictions (line) shows a second burst of release 
starting at day 20 and continuing until day 45.  
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5.4 DISCUSSION 
Retrospective analysis of in vitro release is the use of modern technology and understanding of 
release phenomena towards the interpolation and exploration of prior studies to gain further 
information on a formulation’s performance in the absence of additional experimental data.  For 
instance, published release assays can terminate before drug release is complete or contain 
widely-spaced intervals of time between data points, complicating interpretation of a 
formulation's drug delivery kinetics.  While such data may be suitable for planning initial 
functional assays that evaluate a formulation’s activity, a more detailed understanding of a 
formulation's release kinetics would be useful when refining a formulation design or planning 
Table 3: Extrapolative Predictions 
 
Rp Rocc Mwo kCw MwA Assay End   
End of 
Release  Error Ref 
Agent (µm) (µm) (kDa) (day
-1
) (Da) (Day, %) (Day) (nRSS) 
 
VEGF 2.55 1.84 34 0.0864 21000 28 74 87 2.30E-04 
 3a 
BSA 22.5 5.85 18.9 0.0864 66500 34 26 74 2.20E-04 
 23a 
GM-CSF 25 1.23 40.4 0.0864 22000 7 5 91 2.66E-05 
 23b 
VEGF 2.2 1.05 110 0.0634 21000 30 51 113 9.64E-05 
 23c 
BSA 17.5 5.25 130 0.0864 66500 25 33 66 3.06E-04 
 23d 
Levofloxacin 1180 802.4 80 0.0169 361 46 69 91 7.39E-05 
 23e 
Paclitaxel 25 6.75 100 0.0169 854 30 27 340 1.70E-04 
 23f 
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animal studies, like those for long-term dosing or evaluating disease outcome.  Further, when 
translating formulations to human use, a full understanding of how a biodegradable polymer 
matrix releases an encapsulated agent is extremely important.  To most efficiently plan such 
studies or possibly even make the best decision as to whether or not the studies would be fruitful, 
prior information is needed on: a) how the expected rate of release varies between data points, 
and/or b) if or when additional release can be expected beyond the release assay’s termination. 
One possibility to obtain this information would be to iteratively conduct a series of long-term 
release assays.  However, mathematical analysis of existing release data may offer a tremendous 
time- and cost savings in obtaining this useful information.   
In order to be useful for retrospective analysis, a mathematical model must effectively 
describe or predict a formulation's release kinetics, particularly in the regions where data are 
sparse or non-existent.  The model used herein has an extensive record of validation that 
encompasses PLGA microparticles loaded with a wide variety of drugs (Section 3.3).  
Importantly for this study, the model has demonstrated consistent and accurate predictions of 
both the timing and rate of secondary burst release for small molecule-, peptide- and protein-
loaded microparticulate systems.  These predictive capabilities are essential for handling analysis 
of data sets that lack information about the second burst and therefore require extrapolation.  
Other models would be more suitable for  retrospective analysis of the kinetics of the initial 
burst, poorly soluble agents, or matrix implants, hydrogels, and novel controlled release 
systems
42,96,139
.   
The model-aided analysis used herein can help determine if a formulation actually 
provides an acceptable rate of drug delivery when widely spaced data points leave uncertainly as 
to its release kinetics.  One outcome of this analysis is the ability to use more cost-effective, 
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rapid detection techniques, which would otherwise be eliminated from consideration due to their 
poor sensitivity.  For instance, in the evaluation of enfuvirtide release, mathematical predictions 
can confirm the utility of a microBCA assay in the detection of release over a more expensive 
and lengthier HPLC protocol (Figure 18).  Without supporting model predictions, the 10 day 
sampling interval necessitated by the microBCA assay’s poor detection limit could result in 
missing key changes in release behavior, potentially leading researchers to misinterpret the 
formulation’s variable release rate as “sustained” or “linear”.  This misinterpretation could be 
extremely costly especially since true, sustained or linear release is the most critical desirable 
aspect of many modern release formulations. 
Indeed, the “linear release” design criterion applies to any formulation intending to 
produce constant serum concentration, encompassing well over 50% of the top 200 best-selling 
drugs on the market today
8
.   For example, Figures 2 and 3 contain data sets with gaps of at least 
20 days and more than 40% release that could be assumed to span intervals of sustained release. 
Indeed in the case of lysozyme release, mathematical predictions suggest that release is actually 
sustained from day 30 onward using the described formulation (Figure 19).  This predicted 
profile is consistent with those documented in other sets of release data from lysozyme-loaded 
PLGA microparticles of comparable chemistry and molecular weight
140,141
.  In evaluating release 
of superoxide dismutase, however, predictions suggest that SOD release follows a burst-lag-burst 
pattern, instead of a constant, sustained one, which would have been desirable for an antioxidant 
(Figure 20).   Similar behaviors are reported for a number of other protein loaded PLGA 
microparticles
42
.  Having the ability to evaluate protein release data as sustained or pulsatile, 
without frequent sampling, should become increasingly valuable as work on the controlled 
release of costly cytokines, chemokines, growth factors and other biomolecules continues to 
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expand
142-144
.  In the absence of plots, statistical metrics comparing a linear interpolation to the 
model prediction, such as the normalized residual sum of squares (nRSSi), can indicate if 
changes in the rate of release are indeed occurring between data points.  When assumed point-to-
point interpolation differs significantly from a model prediction, but the data points do not, 
changes in the rate of release are occurring during between sampling points. 
Mathematical analysis can also aid in the understanding of release kinetics when an 
experiment does not reach completion because it is (for whatever reason) terminated after just 
the initial burst phase of release.  Recording only this initial release data is often useful when 
exploring formulations for an entirely new drug candidate or when planning preliminary studies 
with cell functional assays which last for just days or weeks. However, the presence or absence 
of delayed release of drug could be extremely important when refining a formulation design or 
planning extended animals studies.  A case study is provided by a controlled release formulation 
of nitro-fatty acid, a novel anti-inflammatory lipid whose stability in the acidic microclimate of 
degrading PLGA microparticles remains unknown.  Accordingly, a short, 2 week release assay, 
revealed both NO2-OA’s stability and its initial rate of release.  However, this assay documented 
less than 30% of drug delivery.  Clues to the duration of release can come from data on erosion, 
which are responsible for governing release in many hydrolysable polymer systems
42
.  Similar 
polymer microparticles erode most significantly between days 8 and 30
6,41
, defining a window 
when pore formation and erosion-mediated release may occur.  Model predictions during this 
time period have the potential to provide further detail into the actual release behavior.  For 
instance, model predictions suggest that this formulation exhibits release continuing in a 
sustained manner through day 28, which is an appropriate delivery schedule for the eventual 
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clinical application of this active agent.   A subsequent release assay conducted in triplicate 
confirmed the accuracy of the model prediction, lending support for this type of analysis.    
For formulations without sustained release profiles, extrapolative predictions can also aid 
in setting the dosing frequency for subsequent animal studies and the duration of sampling in 
future release assays.  An example of how predictions can aid in setting dosing schedules is 
represented by the analysis illustrated in Figure 22.  The in vitro release data from this 
formulation shows 60% of superoxide dismutase SOD being delivered over 8 days, implying that 
a once-weekly dosing schedule would seem logical based on the experimental data.  Yet, 
mathematical predictions suggest a secondary burst of SOD is imminent at 30 days following the 
start of release.  Based on this information alone, the results may warn a user that repetitive 
administration at 1 week intervals could lead to unexpected release of drug that is over 5 times 
the desired dosing of SOD beginning at day 60.  Retrospective analysis suggests (alternatively) 
that adjusting the dosing interval to once every 8 weeks and repeating the release experiments 
could potentially minimize the simultaneous delivery of SOD from repeat administration while 
still producing the desired effect.  An example of how predictions can aid in setting release assay 
duration is represented by the analysis in Figure 23.  This in vitro data set could suggest that the 
rate of release slows from day 15 until the assay’s close at day 30.   In contrast, model 
predictions suggest that release may actually accelerate between days 20 and 30 instead of 
decelerating.  This behavior would warrant collection of data until day 40 when closure is 
predicted, if it was necessary to experimentally determine this formulation’s maximal rate or 
duration of release.  These information-loss examples are representative of release assays 
conducted on a number of other protein and peptide formulations. This suggests that 
extrapolative mathematical prediction may prove extremely useful when developing 
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formulations for a wide variety of applications and in particular for the delivery biologics or 
poorly soluble molecules, which are noted for often having lengthy release profiles
126,128
. 
However, it is important to note some limitations of the current model for this type of 
analysis.  For instance, the model equations (Section 3.2.2) do not provide a way to predict the 
rate (as opposed to the magnitude) of the initial burst, which is correspondingly over-predicted in 
10 of 19 simulations herein.  Existing mathematics
145,146
 (or future work on the current model 
construct) describing dissolution limitations or electrostatic interactions with polymer matrix 
may serve to account for any systematic, over-predicted release in these cases.   Cumulative 
release was also over-predicted during the last 10-20% of drug delivery in 6 out of the 10 
simulations that include data is this region.  This systemic deviation might be due to the model’s 
approximation of pore formation as a cumulative normal distribution
128
.  A comparison to 
experimental data reveals that this function begins to overestimate the rate of erosion (mass loss 
from the polymer matrix, responsible for pore formation) when just 20% of original mass 
remains
41
.  A more physically accurate description of erosion, perhaps accounting for 
crystallinity among oligomers, might correct this systemic overestimation of final release
93
. 
Regardless, this retrospective analysis (producing in silico data for 20 real-world in vitro 
release assays) is, to our knowledge, the first instance of such use of mathematical modeling 
technology for biodegradable matricesThere are similarities to this kind of analysis to previous 
nascent methods to compute specific pharmacokinetic drug properties (e.g. bioavailability and 
clearance route) in the 1960s
127
.  Since then, pharmacokinetic analysis has grown substantially 
both in the scope of its mathematics and impact of its results.  PK modeling analysis now 
regularly makes predictions for the processes of adsorption, metabolism, distribution, and 
excretion (ADME). It is also now an essential component of the US regulatory approval 
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process
33
.  Furthermore, PK modeling has most recently grown to encompass molecular 
simulations of drug-protein binding in order to predict ADME processes during drug 
discovery
147
.  In contrast, the role of predictive and data modeling has significant room for 
expansion in controlled release formulation development.  Indeed, since Higuchi first 
demonstrated the utility of mathematics for describing solubility limited drug release from a 
matrix system, models have been developed for a number of specific biodegradable polymer-
based drug delivery systems
139,148
.  In practice though, the systematic or statistical design of 
experiments (DoE) is still considered state of the art and is significantly faster than the trial-and-
error approaches used in past decades
20
.  Augmenting DoE with existing models of release 
would be a simple, inexpensive, and rapid way to achieve greater efficiency in the formulation 
development process.  In the future, even further gains could be derived from harnessing 
molecular scale simulations, as done in drug discovery, to predict drug-polymer interactions 
thought to influence release
24
.   We are currently exploring such methods to add power of 
prediction at some expense to the generalizability of the results produced. 
5.5 CONCLUSION 
Predictive modeling is of extreme potential value for the analysis of in vitro release data in much 
the same way that modeling is now considered an integral part PK studies.  The in vitro and in 
silico data presented herein demonstrate predictive modeling as a key for interpreting in vitro 
release assays and planning subsequent studies, either in vitro or in vivo.  By interpolating and 
extrapolating with predictions, the necessary duration of an assay can be determined, the timing 
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of sample points can be set and the suitability of different detection techniques can be evaluated.  
These benefits are not only of interest during formulation design, but also during the 
establishment of quality by design (QbD) manufacturing routines, when connections between a 
formulation’s attributes and performance are established. 
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6.0  CASE STUDY: DELAYED RELEASE VACCINE PLATFORM 
6.1 INTRODUCTION 
Vaccines have arguably had the greatest impact on public health of any known medical 
intervention 
149.  Successful inoculation with several doses of “dead” or disabled pathogen 
produces long-term immunity from highly virulent diseases, some of which have no cure once 
they reach the point of mature pathogenesis 
11
.  Unfortunately, citizens of many developing 
countries frequently do not receive the 2
nd
 or 3
rd
 vaccine doses needed to establish immunity.  In 
fact, the World Health Organization (WHO) estimates that four to five million deaths could be 
prevented annually with complete vaccination 
150
 (“complete” in that patients receive all 
subsequent booster shots
11
). Over half of these deaths are children under age five 
150
.  These 
preventable deaths occur in spite of a long-standing global immunization program (GAVI) 
supported by a partnership between international organizations, national governments, industrial 
concerns and private donors 
24
.  A platform for delayed release vaccination could improve 
effectiveness by ideally allowing a single injection at birth to autonomously provide all requisite 
doses at the correct times.  Because this at-birth approach would target individuals when they are 
most likely to be at a medical facility, it would provide savings not only from reduction in 
number of injections needed but also from reduced reduce administrative costs for record 
keeping and logistics.   
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Figure 24: Comparison of dosing schedules  
Control injections (dark) and heuristically designed DRV(light) from Men et al.  The timing of the 2nd & 3rd doses 
from the best formulation dramatically differs from the optimal delivery times.  Dose magnitudes assume an equal 
distribution of agent between all microspheres. 
 
 
The design of a single shot vaccine has remained a challenge for over 25 years because of 
the complexities of how controlled release formulations provoke an immune response.  Early 
studies revealed that simply prolonging antigen delivery did not promote immunity, but rather 
tolerance 
151,152
.   This promoted development of formulations that mimic the dosing of proven 
vaccines autonomously releasing multiple bursts of antigen over time 
152
.  Researchers have 
produced single injection vaccines that deliver multiple bursts of antigens such as tetanus toxin, 
diphtheria and hepatitis B. 
11,153
. However difficulty arose in replicating the multi-dose 
administration schedules for these real-world antigens because of the trial-and-error methods 
used to tune the performance of the polymer carrier that controlled release 
154
.  As evidence, one 
of the most well thought out formulation design studies to date mimicked the immunization 
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schedule currently used for tetanus toxoid by combining particle sets that burst at different times.    
Out of 5 attempts, the timing of burst release from the best result was over 6 months later than 
suggested by the CDC immunization schedule (Figure 24)
155
.  Such a delay not only altered the 
immune response, but also complicated implementation of the assays needed to measure it.   
Many more studies have used simpler controlled release formulations, examining antibody titres 
elicited from single polymer microparticles documented to provide burst-lag-burst profiles in 
vitro.  However antibody titres are not a direct enough measurement of immune response to 
correlate in vitro release results to in vivo antigen release and in many cases such measurements 
were not extended much beyond the controlled release formulation’s lifespan11,153.  Interestingly, 
one of the few studies to extend titre measurements well beyond the duration of antigen delivery 
concluded that repeat administration 12 months after the original inoculation would be necessary 
to sustain protective immunity
156
. Fortunately, this research prompted further immunological 
exploration of microparticle vaccines by raising questions about the adjuvancy of microparticles 
and the impact of antigen stability.   
To compensate for a lack of long term immunity researchers have enhanced immune 
response by making use of a microparticle’s biomimetic adjuvant potential.  Specifically, 
particles that resemble bacteria in size are taken up by dendritic cells and macrophages at the site 
of injection and then transported to the lymph nodes
52
.  Injection of small (1-5µm) particles has 
been documented to produce strong immune responses to ovalbumin, diphtheria toxoid, tetanus 
toxoid,GP120 (HIV) and many other antigens
157
.  (Particles larger than 5-10µm are not readily 
phagocytized and show much less potential as adjuvants
52
.)  The immediate adaptive immune 
response to a single injection of small particles was in most cases comparable to that of complete 
Freud’s adjuvant or multiple does of protein-alum complex with strong type 1 and type 2 
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responses
11
.  Studies have also documented that the elevation of antibody titres provoked by 
these vaccines extends beyond 1 year, although the role of isotype is not investigated.  From this 
body of work, it is clear that single injection of antigen loaded microparticles can promote a very 
strong immune response, much stronger than can be achieved with conventional FDA approved 
adjuvants and antigens
11,158
.   
Extensive research has also focused on the stability of antigens delivered by microparticle 
vaccines with the view that it might be a major barrier to their clinical application.  During 
microparticle production, storage and administration protein antigens are subject to conditions 
that can cause them to denature or aggregate.  These conditions include high shear and organic 
solvents during production, lyophilization for storage, as well as elevated temperatures and 
acidic conditions following administration
11
.  Accordingly studies have focused on methods of 
protecting protein antigens from these conditions.  Success has been achieved with unique 
antigen-excipients combination such as tetanus toxoid paired with bovine serum albumin and 
trehalose or ovalbumin paired with polyethylene glycol, which have been correlated to higher 
antibody titres
159-161
.  The possibility of encapsulating and releasing intentionally aggregated 
antigen, such as a protein-alum complex, has yet to be investigated.   
When moving forward with proof-of-concept development of a new delayed release 
vaccine, the findings of prior research must be taken into account.  First, if a “boost” is desired, 
microparticles must be able to hide at least some portion of antigen from the body until 
predetermined times.  Proven immunization schedules encompass a number of dosing times 
between 0 and 18 months of life
154
.   Second, the antigen delivered by the microparticles must be 
in a stable and intact form.  Ensuring antigen stability will prevent alterations in the 
formulation’s release kinetics due to unintended aggregation or binding with the polymer matrix 
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as well as loss of antigenicity due to degradation by poly(lactic-co-glycolic) acid oligomers
11
.  
Third, the microparticles must be sized larger than 10µm in diameter, but still be small enough to 
be injected with standard syringes.  This will prevent uptake by antigen presenting cells, which 
not only alters the rate of antigen release, but also causes a prompt and potentially harmful 
adaptive immune response
158
.  
This chapters details the model-aided development and testing of delayed release vaccine 
microparticles.  Polymer stock materials were selected for the microparticles based on 
simulations and successful production of DRV microparticles was confirmed by microscopy.  
The in vitro release behavior of DRVs was subsequently measured and compared to model 
predictions.  In vivo, the DRVs were tested for the capacity to delay antigen release with the 
ovalbumin-specific type II T cell (OT-II) proliferation assay.  The type of immune response 
generated by DRV microparticle depots was further measured with the lysis of SIINFEKL 
pulsed spleenocytes and analysis of serum IgG response by ELISA.   
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Poly(lactic-co-glycolic)acid (PLGA) copolymers were purchased from Evonik Industries AG 
(Essen, Germany).  Specific types were as follows: RG502 (9kDa), and RG504 (30kDa). Grade 
V ovalbumin was purchased from Sigma Aldrich (St. Louis, MO). Alhydrolgel (alum), solvents, 
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assay reagents, and other chemicals were purchased from Thermo Fisher Scientific (Waltham, 
MA).  
6.2.2 Polymer Selection 
In vitro release profiles were predicted for the stock 50:50 PLGA and 75:25 PLGA 
copolymers available with acylated chain ends from Evonik Industries.  For these initial 
predictions, it was assumed that average occlusion size was significantly smaller than polymer 
size (Rocc << Rp).  (Acylated chain ends minimize the fraction of surface-associated occlusions 
and minimal the initial burst
142
.)  These potential release profiles were then compared to target 
windows for delayed release: days 7-12, days 14-19, and days 28-33.  Polymers with the least 
sum-squared error between their predicted release profiles and the targets windows for the DRV 
were selected for use in microparticle fabrication.   
 
 
Table 4: Production Conditions 
 
Sonication Homogenization 
 
Power Time (s) Rate (RPM) Time (s) 
DRV 30% 30 1000 60 
SRF 30% 10 3200 60 
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6.2.3 Formulation Production 
Ovalbumin was adsorbed to alum, as done previously 
162
.  Under sterile conditions, 10mg of 
OVA dissolved in 4.5ml of 0.01DPBS and mixed with 1ml of alum for 30 minutes.  OVA-alum 
was then collected by centrifugation at 10,000 RCF for 1 minute.  The concentration of OVA in 
the aspirated supernatant was measured by microBCA assay and used to calculate the loading of 
the OVA-alum.   
Microparticles were prepared by the double emulsion process detailed in Section 5.2.2.  
Dichloromethane and the dissolved polymer were added directly to the OVA-alum.  To help 
ensure encapsulation of the OVA-alum, the volume and mass of the polymer/DCM phase was 
doubled.  Dispersion of the high viscosity OVA-alum required a sonication time of 30s at 30% 
amplitude instead of 10s at 20% required a more homogeneous primary emulsion.  
Homogenization speed was also decreased to 1000 RPM to increase particles size, which was 
thought to reduce phagocytosis and the initial burst release of OVA-alum.  After preparation 
microparticles were washed for an additional 48 hours to further reduce the burst release of 
OVA-alum and stored at -80
o
C until use. 
6.2.4 Formulation Characterization 
Microparticles were sized using the volume impedance method with a minimum of 10,000 
measurements on a Beckman Coulter Counter (Multisizer 3). Microparticle surface morphology 
and shape were examined using a scanning electron microscope (JEOL JSM-6330F).  
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Formulations doped with OVA-Texas Red were examined with confocal microscopy to 
determine the occlusion size and distribution of active agent within the particles. The loading of 
antigen was measured by dissolving 5mg of microparticles in 250 ul dimethylsulfoxide (DMSO). 
Antigen was then extracted with the addition of 1 ml of 0.05M NaOH / 5% sodium dodecyl 
sulfate (SDS) and its concentration was measured using the microBCA assay.    
6.2.5 In vitro Release Assay 
Release data was measured accumulatively, as done previously13.  Briefly, a known amount of 
microparticles was suspended in 500ul of phosphate buffered saline (DPBS, pH 7.4, GIBCO, 
Invitrogen) and placed on an end-to-end rotator at 37
o
C.   At regular intervals the microparticle 
suspensions were centrifuged, allowing the supernatant to be collected and particles to be 
resuspended in an equal volume of DPBS.  OVA concentration in the supernatant was measured 
on a Spectramax M5 microplate spectrophotometer (Molecular Devices) using the microBCA 
assay as detailed in the manufacturer’s protocol (Pierce, Thermo Fischer).   
6.2.6 Mice 
Female C57BL/6 and B6.SJL-PtprcaPepcb/BoyJ (CD45.1+) mice were used at 6–12 weeks 
of age (Jackson Laboratory, Bar Harbor, ME) for immunization. OVA-specific type 2 T cells 
were harvested from C57BL/6 mice for the proliferation study.  Spleenocytes for the CTL 
lysis study were harvested from C57BL/6 mice. All animals were maintained under standard 
animal house conditions in accordance with Department of Laboratory Animal Research.   
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6.2.6.1 Immunization protocols 
For the OVA-specific CTL lysis and OT-II proliferation assays:  CD45.2 mice were injected in 
the footpads with 2 week delay microparticles containing 20µg of OVA at 4 or 22 days prior to 
the harvest of OT-II cells and spleenocytes.  Positive control mice were injected with OVA-alum 
4 days prior to harvest of OT-II cells and spleenocytes.   
For IgG titre assays:  C57BL/6 mice were injected intradermally with a 1:1 mixture of 2 and 4 
week delay microparticles containing a total of 40µg/300ul OVA-alum (50µl/footpad and 
200µl/abdomen).  As a positive control naïve B6 mice were inoculated with 20µg/150ul OVA-
alum (25µl/footpad and 100µl/abdomen) at days 14 and 28.   
6.2.6.2 OT-II Proliferation Assay 
CD4 T cells were harvested from the lymph nodes (LN) of OTII mice and were purified using 
anti-CD4 MACS microbeads (Miltenyi Biotec Ltd., Bisley, U.K.).  Five x 10
6
 T cells were 
labeled with 5 µM CFSE for 8 minutes then washed immediately 20ml HBSS (serum-free) 3 
times and resuspended 2.5 x 10
7
 for injection (i.v., s.c., and footpad) into recipients. Popliteal 
and inguinal lymph nodes harvested 96 hours after transfer and dispersed into cells through a cell 
strainer.  Harvested cells were labeled with Anti-CD45.1-PE (A20) and CD4-PerCP-Cy5.5 
(RM4-5) and analyzed for reduction CFSE concentration in CD4+ and CD45.1+ cells by flow 
cytometry on a BD LSRII with CellQuest software (BD Biosciences). Final analysis and 
graphical output were performed using FlowJo software (Treestar, Costa Mesa, CA). 
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6.2.6.3 Measurement of ova-specific CTL lysis  
Spleens were collected from naïve B6 mice and cells were collected in sterile PBS through a cell 
strainer.  Spleenocytes were isolated with red blood cell lysis buffer and washed 3x with PBS.  
Naive syngeneic spleenocytes were resuspended in RPMI and split into two equal populations.  
One set was pulsed with 100 µg/ml SIINFEKL for 1 hour at 37
o
C and labeled with 5µM Horizon 
V450 (V450hi).  The other set was incubated for 1 hour without SIINFEKL and labeled with 
either 0.5µM V450 (v450lo) (Molecular Probes, Eugene, OR, USA). Labeled and pulsed cells 
were subsequently mixed at a 1:1 ratio and approximately 10
7
 cells were injected intravenously 
into immunized mice. After 12h, mice were killed and spleenocytes were collected as done in 
Section 6.2.6.2.  Spleenocytes were then fixed and analyzed for the disappearance of V450 by 
flow cytometry on a BD LSRII with CellQuest software (BD Biosciences). The percentage of 
OVA-specific lysis was calculated as follows: % specific lysis = (1 - ((ratio of V450lo/V450hi in 
naive mice)/(ratio of V450lo/V450hi in immunized mice))) x 100. 
6.2.6.4 Titre measurement of IgG1a and IgG2c 
Two weeks after the completion of vaccination, serum concentrations of ova specific 
immunoglobulin was measured by ELISA as done previously
163
.  Blood was collected from each 
mouse by cardiac puncture and centrifuged to isolate serum. For the ELISA, OVA coated plates 
were washed (1:2200 tween), blocked with 10% FBS (1hr) and washed again prior to a 2hr 
incubation with serum samples. Plates were washed and secondary antibodies for IgG1 and 
IgG2c (1:20,000 dilutions, 10% FBS) were added for a 1hr incubation. Plates were washed and 
incubated with avidin-horseradish peroxidase conjugate (HRP, 1:1000 in 10% FBS) for 45min.  
Plates were washed and then developed with alternate exposure to TMB and 0.01M sulfuric acid.  
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Titres were determined by calculating the dilution required to achieve a cut-off o.d. reading of 
0.2, and were expressed as the reciprocal of that dilution. 
6.3 RESULTS 
Literature includes a wealth of articles documenting the development of microparticle vaccines 
via experimental methods
11,152,155,161,164-173
.  These articles often include tables listing varied 
manufacturing parameters or material properties and figures documenting each variant’s in vitro 
release behavior. In this chapter formulation development began with in silico predictions to 
calculate which materials would be best for production of the required delayed release 
formulations.  Each DRV was then produced and tested in vitro for its release profile.  In vivo 
studies were then performed to determine how the immune response compared to controls 
including manual administration of unencapsulated antigen and adjuvant at specified times. 
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Figure 25: In vitro release of OVA from delayed release microparticles measured by spectraphotometry.  
 Model predictions appear as blue lines, dissolution of OVA-alum is shown with green dots and release from 
microparticles is shown with red circles.  Microparticles of A) RG502H displayed a significantly burst B) RG502.  
SEM inserts show internal morphology of each microparticle set.  
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6.3.1  Formulation Designs and In vitro Release 
Simulations were performed to determine the best materials for the DRV applications.  
Computations were initialized based on the rate of OVA dissolution from OVA-alum and a delay 
of 1, 2, or 4 weeks.   Calculations identified 50:50 PLGA copolymers with molecular weights of 
12kDa, 21kDa, and 53kDa as the most suitable materials production of the DRVs.   Acylated and 
acid end capped versions of the 12kDa polymers both tested for their effect on release (Figure 
25).  Results were also compared both to dissolution data from OVA-alum and model 
predictions.    Because the acylated polymer yielded a lower initial burst than the acid end 
capped, this type chemistry was used for the 21kDa and 53kDa polymers as well.  In vitro 
release assays confirmed that formulations produced from these model-identified materials 
yielded release profiles in line with both model predictions (Figure 26).   
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Figure 26:  Microparticle formulations tailored for 2 and 4 week lag phases.   
Vertical dotted lines indicate the start of weeks 2 and 4.  In vitro release data appears as points and corresponding in 
silico predictions appear as lines. The loading 2 week (blue) and 4 week (red) formulations were measured at 
19.2µg/mg and 26.0µg/mg, respectively.   
6.3.2 Formulations Properties  
The DRV microparticles were produced by double emulsion and analyzed by SEM.  
Microparticles lyophilized immediately following fabrication were found to have a rough surface 
morphology that became significantly smoother following the 48hours of washing used to 
remove the initial burst (Figure 27).  Confocal microscopy across microparticles’ widest plane of 
focus shows that the majority of OVA-alum is encapsulated within the DRV in discrete 
occlusions (Figure 28).  This internal distribution of antigen is similar to the pattern discrete 
occlusions surrounded by dense a polymer matrix imaged via SEM (Figure 25B, insert).  Sizing 
by the volume impedance method yielded volume-averaged diameters of 25.4±7.8µm and 
19.2±7.4 for DRV and SRF particles respectively (Figure 29).  This ensures that 99.6% of the 
DRV particles are greater than 5µm in diameter.   
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Figure 27:  Comparison of OVA-alum microparticles A) pre- and B) post- wash. 
A) Post fabrication lyophilized microparticles display a rough morphology.  B) After washing in PBS for 48 hours, 
microparticle morphology becomes significantly smoother.  Scale bars are 10μm.   
 
Figure 28: Confocal microscopy analysis of 4 week DRV formulation. 
 Doping of particles with OVA-alexa fluor 647 conjugate shows antigen grouped in well-defined occlusions and 
scattered on the particle surface.  Select microparticles in the plane of focus have been ringed with dashed yellow 
lines under higher contrast to highlight their boundaries.  Scale bar is 10µm.   
A) B) 
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Figure 29: Sample sizing result from DRV particles.   
Almost all of the antigen (99.5%) is found in particles that are too large to phagocytose (> 5um diameter). 
 
6.3.3 In vivo testing of the DRV 
The alum adjuvant used in the DRV formulation is noted for promoting an Th2 immune 
response, but phagocytized microparticles are noted for promoting a strong CTL immune 
response.  Assays of both Th2 and CTL responses to antigen presentation throughout the 
duration of antigen release will be needed to assess how model-designed microparticles perform 
in vivo.  An attempt was also made to isolate and evaluate dendritic cells for the uptake of 
fluorescently labeled OVA.  However, this cell population proved too scarce to provide a 
sensitive measure of antigen presentation. (Data not shown) 
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6.3.3.1 OT-II proliferation 
The day 4 and 22 sample points used in the OT-II proliferation assay capture both periods of lag 
and periods of active antigen release from the DRV microparticles shown in Figure 26.  The OT-
II response to the DRV microparticles at day 4 was significantly lower than the positive OVA-
alum control or microparticles, post-burst at day 18 (p<0.001).  OT-II proliferation at the later 
time points rivaled the maximal response to an equal injection of OVA-alum, reported to occur 
four to six days post immunization (Figure 30). 
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Figure 30: Comparison of OT-II cell proliferation from DRV microparticles and control vaccines 
Proliferation of OT-II cells was charted by reduction in CFSE concentration and gates were drawn based on naïve 
mice.  Typical OT-II proliferation results for A) OVA-alum 4 days post injection, B) DRV microparticles 4 days 
post injection and C) DRV microparticles 22 days post injection appear as shaded lines.  In each histogram (A, B, C) 
proliferation results for a characteristic naïve mouse appear as a solid red peak.   B) Fold increase in proliferation 
results from the DRV microparticles at day 22 and OVA-alum group are significantly higher the DRV microparticle 
at day 4 (p < 10
-5
, n=3).   
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6.3.3.2 OVA-specific CTL lysis 
Protein alum vaccines are not typically associated with strong cellular immunity.  However, 
microparticle phagocytosis can generate a prompt CTL response.  Two injections of OVA-alum 
(days 0 & 7) only reduced SIINFEKL-pulsed spleenocyte populations by as much as 18.4±3.1%.  
An equivalent two dose ovalbumin microparticle vaccine (one injection, Figure 25A) produced 
comparably low killing of pulsed spleenocytes (max = 20.6±5.4, Figure 31).  In contrast, this 
CTL activity assay produce killing of more than 90% for a single dose gene-gun vaccine.   
 
Figure 31: OVA-specific CTL lysis 
The two injection ova-alum vaccine and two dose microparticles generate CTL responses at 19 and 26 days post 
inoculation that are not statistically different at p < 0.15. 
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6.3.3.3 IgG1 and IgG2c titre 
 Antibody titres are not as immediate (or sensitive) a measurement of immune response as CTL 
lysis or OT-II proliferation.  However, they do offer a means of determining if the overall isotype 
of a delayed release vaccine differs from that of a matching OVA-alum vaccine.  This chapter 
compared IgG responses from an ova alum vaccine with doses at day 0 and day 14 (positive 
control) to a DRV that release OVA-alum at two and four weeks post injection (Figure 26).  For 
both vaccines IgG1 titres were 3-5 times higher than the IgG2c titres (Figure 32).  Also the titres 
generated by the OVA-alum and delayed release vaccines are indistinguishable at alphas up to 
0.5 or higher.  ELISA titres measured 8 weeks after inoculation were negligible in all groups 
(data not shown). 
124 
 
Figure 32:  Titres of OVA-specific IgG2c and IgG1 antibodies.  
Serial dilutions of serum samples were performed to ensure detection of A) IgG2c and B) IgG1.  Serum from mice 
immunized with OVA adsorbed to 1-5µm iron beads (IgG+) was used as an internal control to confirm successful 
completion of the assay.  Based on the dilution data, the 1x groups were selected for further evaluation.  C) OVA-
alum and DRV produced comparable fold increase in antibody titres over naïve.  As expected for alum adjuvant, 
IgG1 titres were significantly higher than IgG2c for both groups. (p  < 0.006) 
B) 
A) 
C) 
125 
 
6.3.4 Results Summary 
Microparticles engineered for delayed antigen delivery displayed in vitro release profiles that 
match model predictions.  In vivo these particles elicit a strong OT-II response following antigen 
release, but not before it.  Antibody titres and CTL lysis results also show that the microparticles 
do not skew the response to the OVA alum antigen.  These results are comparable to 
unencapsulated OVA-alum, which generates immunity where the humoral (type 2) response is 
characteristically stronger than the cellular (type 1) response.   
6.4  DISCUSSION 
Testing of the delayed release vaccine (DRV) platform from this chapter demonstrates that 
antigen can be masked from the adaptive immune system by microparticle carriers and then 
revealed at set times to provoke a specific immune response.  Generating this proof-of-concept 
data required new microparticles designed specifically to suppress the initial burst and provide a 
set lag or delay prior to antigen release.   These particles delivered ovalbumin antigen co-
encapsulated with alum, a common vaccine adjuvant known to promote a strong type II immune 
response.  Because microparticles can prompt a type I response, this DRV design allowed 
changes in vaccine adjuvancy to be documented clearly though T cell activity studies and 
antibody titres.  These studies add new information on how formulations can be custom-designed 
to tune the timing of vaccine delivery without changing the type of the immune response.   
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All four DRV formulations (burst-lag-burst in Figure 24A, 1 week delay in Figure 24B, 2 
week delay in Figure 25, and 4 week delay in Figure 25) designed in this chapter produced in 
vitro release profiles conforming to model predictions, a prerequisite for animal studies.  Early 
work on microparticle vaccines produced designs with burst-lag-bursts or continuous release 
profiles, but yielded no clear metric for controlling in vitro antigen release and the need for 
delivery systems whose release kinetics can be precisely tuned continues to be cited today
157,174
.  
When evaluated for specifically timed, delayed antigen release, the 30 year body of literature on 
controlled release vaccines includes numerous examples where the timing antigen release has 
been altered or the initial antigen release suppressed, but none where both features are found 
together
157,169,174
.  As evidence, researchers developing depot formulations with timed bursts of 
antigen release typically tested 7 designs in order to discover the one or two where the duration 
of release was suitable for animal study
155,156,164,170,172,175
.  Similarly, in one of the few studies to 
demonstrate delayed release (less than 7% initial burst) the five different designs tested all 
released Hepatitis B antigen between days 40 and 50
161
.  More recent work has shifted from the 
design of specific antigen release profiles and towards the enhancement of vaccine adjuvancy 
with microparticles that are designed to be taken up by the antigen presenting cells (APCs)
174,176-
182
.  In the low pH environments of APCs lysozomal compartments microparticles rapidly 
degrade instead of producing burst-lag-burst or delayed release profiles
38,52
.  In contrast, larger 
microparticles (>5μm diameter), like the DRV formulations tested in this chapter, establish 
depots once injected and can be engineered deliver multiple, delayed antigen doses, 
autonomously replicating the administration schedules for vaccines such as DPT, Hep. B, 
Rotavirus, Hib, and inactivated Polio.  However, the success of this depot-based immunization 
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strategy depends, not only the microparticle vaccine’s release profile, but also its ability to 
deliver antigen and adjuvant intact.   
Many reviews on microparticle vaccines cite antigen stability as a major hurdle to 
establishing protective immunity with a single injection and the strategies adopted for increasing 
antigen stability are diverse
11,152,157,174
.  Researcher have co-encapsulated sugars, synthesized 
novel materials, and even produced formulations with surface-bound, instead of encapsulated, 
antigens
11
.  These approaches, however, are not easy to integrate into a delayed release vaccine.  
Both novel materials, such as polyethylene glycol copolymers, and surface adsorption strategies, 
would alter the antigen’s release profile from the desired lag-burst pattern183,184.  Similarly small 
molecule excipients, like mannitol, release from formulations much more rapidly than proteins 
and show correspondingly less protection at late points in time, specifically when a DRV 
delivers antigen
77,185,186
.  Instead of taking one of these approaches, the strategy adopted for 
stabilizing antigen in this chapter comes from a non-vaccine protein controlled release 
formulation.  Nutropin® Depot, the only protein-loaded PLGA microparticles ever to achieve 
FDA approval, stabilized human growth hormone in complexes with zinc salts
74,187,188
.  This 
payload bears resemblance to protein-alum complexes found in diphtheria, tetanus toxoid and 
other vaccines
149
.  Accordingly the present work microencapsulated OVA-alum using a double 
emulsions process similar to the one used in the production of Nutropin® Depot and 
demonstrated immunogenicity. 
An immunologically successful DRV design was defined as one that would match the 
strong type II immune responses generated by OVA-alum, without also generating the 
measureable type I cell mediated immune attributed to the phagocytosis of 
microparticles
11,189,190
.  In the present work, OVA-specific Th2 proliferation and IgG1 ELISA 
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assays detect measureable type II immune responses from the DRV microparticles following 
antigen release.   Prior use of the OT-II proliferation assay on OVA-alum vaccines has generated 
comparable proliferation responses to the unencapsulated OVA-alum positive control used in 
this chapter
189
. Other microparticle vaccines have also been tested with the OT-II cell 
proliferation assays, but these formulations were not designed to mask antigen as done in the 
present Chapter
168,181
.  Instead, this prior work documents a strong immediate response to < 5µm 
microparticles that act as adjuvants by passively targeting antigen presenting cells
168,181
.  These 
adjuvant-sized particles have also been documented generate a strong type 1 immune response 
through the lysis of SIINFEKL-pulsed spleenocytes and levels IgG2c titres, the two metrics used 
in this Chapter
11
.  Because no Type-I response was anticipated from OVA-alum, or indeed 
detected, gene gun and OVA adsorbed to iron beads were used as also positive controls in 
addition to OVA-alum.  Results from these controls are consistent with well-functioning CTL-
lysis and ELISA assays of other gene gun and particle vaccines
190,191
.   These studies of type I 
response, along with the positive OT-II and IgG1 results confirm that the DRV formulations 
tested do not alter alum’s intrinsically Type 2 adjuvancy.   
While the ability to autonomously deliver antigen is essential, the issue of payload size 
must be considered as well if moving forward with the development of the delayed release 
vaccine platform.  In the OVA mouse model, doses of at least 10µg OVA (with alum)/50µl/hind-
footpad are required to generate significant T cell proliferation, which is among the most 
sensitive metrics immune responses
189
.  This dosing level of approaches the upper concentration 
limit for the delivery of microparticles via a 25G needle (25mg of particles per mL).   Doses 
more than 7 times higher than this level are used in assays that test protective immunity
190
.  
Clinical vaccines offer more leeway with doses as low as 10µg of antigen per ml for the 
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Hepatitis B vaccine, but significant improvements to loading or administration are still required 
for further testing in the OVA mouse model.  This may be achieved with a different 
microencapsulation process where a core of lyophilized antigen-adjuvant is coated with 
biodegradable polymer
192
.   
6.5 CONCLUSIONS 
The aim of the chapter was to design PLGA microspheres that would mask the injection of 
antigen for a specific period of time without otherwise skewing the immune response.  Insights 
from the mathematical model developed in Chapter 3.0 guided the selection of polymers that 
would delay release of antigen release for 1, 2 or 4 weeks.  Testing of these DRV microparticles 
in the OVA mouse model strongly suggests that microparticles do indeed hide antigen.   Results 
also show that the depot-sized microparticles do not skew the type II response provoked by the 
alum adjuvant towards a type I response, which would be indicative of microparticle 
phagocytosis.  This DRV platform, if successful in disease relevant animal models, may provide 
a template for autonomously delivering common vaccines through a single injection at birth.   
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7.0  CASE STUDY: A SUSTAINED RELEASE FORMULATION  
7.1 INTRODUCTION 
Developing a platform that sustains a constant rate of drug release over weeks or months without 
a permanent implants has continued to challenge controlled release engineers since the early 
1980s
193
.  Successes achieved thus far typically involve large synthetic drugs with wide 
therapeutic windows
194
.  The one exception, Nutropin® Depot, had its FDA approval withdrawn 
in 2004 for financial reasons.  A study of the literature on macromolecule formulations reveals 
that peptide and protein release from PLGA microparticles typically begins with a significant 
initial burst (>20%) and often includes a lag before any subsequent release 
5,6,30,43,68,70,72,73,80,100,104,108,109,195
.  Methods of altering this naturally triphasic release profile 
abound (as reviewed in Chapter 2.0 ), but all still require extensive experimental work to 
initialize mathematical models or otherwise precisely tune release.   
Beyond PLGAs a number of other biodegradable and bioresobable polymers have been 
developed specifically for controlled release.  A case example is polyanhydrides, which were 
designed to degrade much faster than their polyester counterparts.  The rapid degradation of 
polyanhydrides was postulated to cause erosion preferentially from the surface inward, thereby 
releasing drug at a much more constant rate than bulk eroding PLGA microparticles
53,196,197
.  
Experiments on the release of hydrophobic drugs from large polyanhydride matrix implants did 
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confirm their ability to sustain release. Recent mathematical models, including our own in 
Chapter 4.0 , show that this linear or sustained release behavior is not maintained for smaller 
matrices or very hydrophilic, small molecule drugs
41,126
. Even without this limitation, the design 
of polyanhydride matrices has remained limited by the absence of a predictive model.  The same 
is true for new biodegradable polymers designed specifically for even better sustained release, 
the stabilization of protein cargos, or ease of injection.  Hydrogels of polyethene glycol or 
polyaminoacids, polyphosphoazines, cross-linked dextrans and drug-polymer conjugates all must 
be tuned through iterative experiments and in many cases require modification of the materials’ 
chemistry to achieve the desired release behavior
187,198
.  Further, the library of data on these 
newer polymers is not yet complete enough to support the development and validation of a 
predictive mathematical model.  Simply put, literature does not include any case of ab initio 
mathematically engineering a formulation that sustains a constant rate of release over weeks or 
months.   
As demonstrated in Chapter 6.0 , the math model developed in Chapter 3.0  can be used 
to predict the release profiles of theoretical polymer matrices.  Data in Figure 12 even suggests 
that a combination of PLGA polymers can be used to sustain release.  Testing of the sustained 
release concept could focus on development of formulation that delivers a water-soluble 
macromolecule for as little as one month.  This goal would provide a proof of concept challenge 
on par with the develop of nutropin depot
199
.  Macromolecules therapeutics also provide a very 
clinically relevant scenario for testing the benefits of controlled release because they are not 
noted for naturally releasing at a constant rate and their delivery currently requires frequent 
injections, which makes them A) painful to administer and B) a high non-adherence risk
12,42,200
.   
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When considering pharmaceutically relevant macromolecules for a case study, the 
peptide drug enfuvirtide (T20) is of the utmost interest.  The drug is currently delivered in two 
daily 90mg bolus injections which sustain a 2.94 mg/L serum concentration in highly infirmed 
patients
201
. This administration schedule makes adherence to enfuvirtide prescriptions 
challenging
202
. In the body, enfuvirtide is rapidly metabolized by proteases that consume nearly 
90% of each injection 
201
. Encapsulation in PLGA microparticles may protect this peptide from 
degradation and lower treatment costs by using the peptide more efficiently.  Finally, as one of 
the only approved HIV fusion inhibitors, which prevents viral entry into T cells, a sustained 
release formulation of enfuvirtide could be used to treat HIV prophylactically and may prove 
more successful than oral prophylactics, which have been significantly hampered by poor 
adherence in clinical trials
203
.   
To the best of our knowledge, a FDA-approved, controlled release formulation of 
enfuvirtide has yet to be realized. Recent efforts by the pharmaceutical company Trimeris Inc. 
have focused on developing controlled release versions of similar anti-HIV peptides in their 
product pipeline (TRI-1144 and TRI-999), using novel technologies, such as entrapment in an 
organic salt complex or in situ forming gel
204
.  At its best, the organic salt formulation 
maintained near-constant rate of drug delivery over two weeks following a distinct initial burst 
(Figure 33).  However, noticeable fluctuations also occurred in the in vitro release rate before the 
assay was terminated on day 16, with just 50% of drug being released.  Results from the gel 
formulation showed even more variability in release data (data not shown)
204
.   Although both of 
these formulations offer improvements over the rapidly metabolized peptide solution delivered 
by bolus injection, resorting to these novel technologies has not necessarily brought researchers 
significantly closer to obtaining desirable release profiles with a formulation that will swiftly 
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progress through US regulatory mechanisms. In PLGA formulations, enfuvirtide sustained 
release has only been documented for 72 hours before ceasing 
205
. However, longer, more linear 
release of this drug holds the potential to improve patient quality of life both through less-
burdensome administration and reduced treatment cost. 
Figure 33: In vitro and in vivo enfuvirtide delivery profiles from a controlled release formulation.[78]   
The novel peptide-organic salt complex formulation fails to maintain constant plasma concentrations of the anti-HIV 
peptide or provide a constant rate of drug delivery. 
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In this chapter, we develop a sustained release formulation engineered for the month-long delivery of enfuvirtide 
and other macromolecules.  The model from Chapter 3.0 was employed to identify a suitable combination of 
polymers for this application.  The resulting formulation contained three microparticle components whose in vitro 
release profiles were assayed with either a dextran Texas Red conjugate or enfuvirtide.  The enfuvirtide formulations 
that performed in accordance with model predictions of in vitro release were tested for activity using a cell-based 
HIV infectivity assay.   
7.2 MATERIALS AND METHODS 
7.2.1 Materials 
Acylated poly(lactic-co-glycolic) acid (PLGA) copolymers RG502 (Mwo ≈ 9kDa) and RG504 
(Mwo ≈ 30kDa) were purchased from Boehringer Ingelheim (Ingelheim, Germany).  Acid end-
capped 50:50 poly(lactic-co-glycolic) acid (4.6kDa) was purchased from Lakeshore Biomaterials 
(Surmodics, Inc.).  Enfuvirtide (T-20) was obtained through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH from Roche. Solvents, assay reagents, and 
other chemicals were purchased from Thermo Fisher Scientific (Waltham, MA). 
7.2.2 Microparticle Production 
Microparticles were produced by the double emulsion process as done in Section 5.2.2  (Table 
4).  Enfuvirtide was dissolved at 2mg/ml in a solution of 22.55 mg/ml of mannitol and 2.39 
mg/ml of sodium carbonate.  200ul of enfuvirtide solution was sonicated in 4ml of 
dichloromethane with 200mg of PLGA.   This mixture was homogenized in 2% PVA and the 
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dichloromethane was allowed evaporate over 4 hours before microparticles were collected by 
centrifugation.   
7.2.3 Microparticle Characterization 
Microparticles were characterized by size, loading, surface morphology and internal morphology 
as done in Section 6.2.4.  Microparticle size distribution was measured by the volume impedance 
method.  The loading of enfuvirtide was measured by dissolution in DMSO and extraction in 
50mM NaOH / 5% SDS.  Scanning electron microscopy was used to evaluate particle surface 
morphology and laser confocal microscopy was used to determine the internal distribution of 
drug within the microparticles.  
7.2.4 HPLC detection 
High pressure liquid chromatography (HPLC) was used to measure the concentration and 
stability of T20 released from microparticles as done in Section 5.2.4.  Samples of releaste from 
T20 microparticles were diluted 1:20 with 35:65 ACN:H2O containing 175µg/ml porcine insulin.  
Standards of T20 (serial dilutions: 20-0.04µg/ml) were assayed at a 1:20 dilution with 35:65 
ACN:H2O as well.  A standard curve was calculated from the ratio blanked peak areas for the 
two T20 peaks and one peak for insulin.   
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7.2.5 Enfuvirtide (T20) Stability Calculations 
Unencapsulated enfuvirtide possessed two HPLC peaks that changed magnitude following 
encapsulation and release.  To calculate stability, the heights of these two peaks were set relative 
to a 100% scale for both the released (post-encapsulation) and unencapsulated enfuvirtide.  The 
percent stability was then calculated based on the ratio of the pre- and post- encapsulation peaks 
for “active” enfuvirtide.   
7.2.6 T20 Activity Testing 
The activity of enfuvirtide was tested using a single replication cycle infectvivty assay as done 
previously
206
.  Briefly, TZM cells cultured in DMEM (90%), 10% FBS, 100 units of Penicillin 
and 0.1 mg/ml of Streptomycin, were plated in 96 well tissue culture plates at 2.5 x 10
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cells/well. Five-fold dilutions of releaste from t20 loaded or 3 fold dilutions of releasate from 
blank microparticles were added plated cells.  Standard curves were prepared with serial 
dilutions of T20 spanning 10,000 to 0.01ng/ml.  All groups described above were prepared and 
tested in duplicate.  Following a 24 hour incubation, virus stock (at 50%ID, as determined 
previously 
207
) was added to all wells and 37°C incubation was continued for 2 days.   Then cells 
were lysed and analyzed with a luciferase assay (Promega).  As a control, standard curves of T20 
(10,000 to 0.01ng/ml and 0ng/ml) were incubated with plated cells (no virus), which were lysed 
after 72hours and measured luciferase baseline and cell health (via MTS assay).   
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7.3 RESULTS 
The performance goal for the design of the sustained release formulation (SRF) platform 
is the month long delivery of a peptide of protein.  Based on this goal, predictions made using the 
model in Chapter 3.0  identified a mixture of three microparticles types that sustain release of 
T20 for one month (Table 5).  Because detection T20 release required implementation of a new 
HPLC protocol, a preliminary formulation was created using 3kDa dextran-Texas Red (dexTR) 
conjugate, which was predicted to have the same release kinetics as T20.  Imaging of these 
particles by SEM revealed these particles to have uniformly smooth surfaces and a spherical 
shape (Figure 34A). A similar morphology was observed for T20 loaded microparticles as well 
(data not shown).  Confocal microscopy of the dexTR microparticles revealed drug occluded in 
small pockets scattered randomly throughout the polymer matrix (Figure 34B).   This 
microscopy data is indicative of a formulation that supplies little initial burst release as detailed 
in Section 3.2.1,  Figure 7.   
 
Table 5:  Composition  of 
50:50 PLGA Mixture 
Mw (kDa) Amount (%) 
5.8 ± 1.5 20.1 
10.2 ± 1.4 31.8 
31.8 ± 2.3 48.1 
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Figure 34: Scanning electron and confocal microscopy images of particles from SRF formulation.   
SEM images of A) RG502 and B) RG504 particles show uniform shape and smooth surface morphology.  Confocal 
images of C) DLG1A, D) RG502 and E) RG504 microparticles show Dex-TR (representative of T20) dispersed 
throughout the matrix. (Scale bars are 10µm) 
A) B) 
C) D) E) 
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In vitro release testing from the dexTR loaded formulation confirmed that each component 
microparticle of the formulation released according to model predictions and, in combination, 
produced a linear release profile (Figure 35).  Comparable results were achieved with particles 
mixed in model prescribed ratio prior to in vitro testing (Figure 36).  This successful validation 
of the formulation design with dexTR provided grounds for testing the design with the 
therapeutic peptide enfuvirtide.   
 
Figure 35: In vitro release of DexTR from SRF microparticles.  
A) In vitro release (dots) follows model prediction (line) release for each formulation. B) When combined at the 
model-defined ratio these individual release profiles continue at a near-constant rate for 30 days. 
A) B) 
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Figure 36: In vitro release from the model defined mixture of DexTR microparticles.  
Experimental data is shown with green dots. Predicted release for the microparticle mixture appears as a dashed red 
line. Model solutions were computed at times corresponding to each experimental data point and linearly 
interpolated.  The target rate of release is indicated with a solid blue line.   
 
Because enfuvirtide lacked the fluorescent label of dexTR, measurement of its in vitro 
release was slightly more complicated.  Implementation of the HPLC protocol for detecting T20 
in serum described in Section 7.2.4, yielded a standard curve that followed a power expression 
from 0.04µg/ml to 20.00µg/ml (Figure 38).  This detection range allowed the successful 
detection of T20’s in vitro release (Figure 37).  A comparison of the predicted and in vitro 
release profiles yielded mixed results.  Both the 9kDa and 30kDa formulation performed in 
accordance with model predictions.  However, release from the 4.6kDa polymer matrix was 
significantly slower than predicted.  In fact, the measured in vitro release profile more closely 
mimicked the predicted behavior of larger macromolecule, such as a protein, rather than that of 
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the 4.5kDa peptide, T20.  Because 4.6kDa polymer was the only one with acid-terminated chain 
ends, matrix charge may play a role in the observed deviation.  This speculation aside, the in 
vitro release data from the T20 formulation confirms that 2 of the 3 component microparticles 
tested do indeed follow model predictions, making them suitable for activity testing.   
 
Figure 37: In vitro release of T20 from three model-defined component microparticles of SRF  
Experimental data measured by HPLC are shown as triangles and predictions are shown with lines.  A) T20 release 
from DLG1A polymer microparticles more closely followed behavior anticipated for protein (dashed  line) than for 
the 4.5kDa peptide, enfuvirtide (solid line).  B)   Data from RG502 (green) and RG504 (red) polymer microparticle 
closely matched model predictions.    
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7.3.1 Enfuvirtide Activity Results 
Microparticles of PLGA produce an acidic microclime as they hydrolyze, which can denature or 
degrade sensitive peptide and protein cargos.  If these changes occur, the rate of active agent 
release can be altered from model predictions.  Because of this, released enfuvirtide was assayed 
both for stability and activity.  
 
Figure 38: Detection of T20 by HPLC.  
Area of T20 peak was zeroed against blank and then normalized by an insulin internal standard. The trend line is y = 
0.0191x
0.8700
; r
2
 = 0.944.  Data point size is indicative of error (n = 3). 
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7.3.1.1  Measurement of T20 stability 
When a peptide is degraded, in a complex with the polymer or aggregated, it exhibits a shift in 
retention time that can be detected with HPLC.  Prior to encapsulation, T20 exhibited two minor 
peaks accounting for 5% and 0.5% of the overall composition.  At lower T20 concentrations 
(more likely to be found in releasate) the smallest peak was undetectable. Further, the main and 
minor peaks accounted for 90±7% and 10±7% of T20 respectively due to the sensitivity of 
HPLC measurements. Following encapsulation and release, peptide stability was largely 
maintained for each of the component formulations in the SRF.  Table 6 lists the % of peptide 
remaining intact for each formulation during periods of measurable release (i.e. when release 
was consistently above the detection limit).    
Table 6: T20 Stability via Analysis of HPLC Peak Areas 
Formulation A (4.6kDa) B (9.0kDa) C (30kDa) 
Window (day) 10-19 8-18 23-30 
T20 Intact (%) 83 ±  4% 83 ± 19% 72 ± 23% 
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7.3.1.2 Measurement of T20 inhibition of viral replication 
When examining the potential of using the sustained release formulation of T20 for HIV 
prophylaxis depends on both release kinetics and the activity of the released drug.  Assessment 
the T20 releasate’s ability of prevent HIV infection was made using the TZM cell functional 
assay.  Sensitivity was documented over a range of 0.027ng/ml to 330ng/ml below which <5% of 
cells were uninfected and above which >95% of cells were uninfected (Figure 39).  A sigmoidal 
fit to this data, yields IC-50 and IC-90 values of 11.1ng/ml and 139ng/mL, respectively.  An 
MTS assay conducted on TZM cells exposed to microparticle releasate or stock enfuvirtide 
showed no significant change from naïve cells, confirming that the infectivity assay results are 
not an artifact of diminishing cell health (data not shown).   
Figure 39: Luciferase expression of TZM cells exposed to HIV in the presence of T20. 
 Infectivity data (red dots) were fit by a sigmoid function (solid blue line) scaled to average max and min luc 
expression, as shown on graph.  Least squares optimization yielded a = 2.0±0.7 and b = -1.7±0.2 (bounds of a 95% 
confidence interval, dotted blue lines). Goodness of fit: SSE = 5955 and r
2
 = 0.993. (Prior to analysis, data was 
normalized by the baseline expression of luc, 528.5 data not shown.)   
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With the sigmoidal fit standard curve, the concentration of active enfuvirtide in releasate 
samples was back calculated.  The cumulative release of active T20, as measured by the TZM 
assay, closely follows overall T20 release as measured by HPLC for formulations B and C 
(Figure 40).   Formulation A was not tested for activity because its release kinetics did not follow 
model predictions.  
 
Figure 40:  The rate of active T20 release (green circles) follows model predictions (red lines).   
Active and stable (HPLC, blue triangles) T20 also release at the comparable rates.  The cumulative release of active 
T20 (green circles) was calculated from infectivity assay results and standard curve in Figure 39.  Loss of T20 
activity at later times (lower concentration) may lead to higher than predicted initial release in A. 
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7.3.2 Results Summary 
The model-guided development of a platform for sustained macromolecule release 
produced a unique formulation composed of three microparticle components.  When tested with 
a model agent, dexTR, all three of these component matrices performed as predicted.  However, 
when T20 was supplemented for dexTR, only 2 of the 3 formulation performed as predicted.  
These two successful designs were tested for activity, which was found to vary little over the 
duration or release.  
7.4 DISCUSSION 
The design of a platform for the sustained delivery of macromolecules could improve patient 
adherence by as much as 85%.  This chapter generated proof-of-concept data for its sustained 
release formulation on the delivery of enfuvirtide for 1 month.  Polymers were selected for this 
formulation based on predictions from the model in Chapter 3.0  as opposed to a variation-of-
parameters, experimental approach that is the current state of the art
19,20
.  With the exception of 
the 4.6kDa acid end-capped polymer, release profiles were comparable for enfuvirtide and a 
texas-red labeled dextran “peptide” surrogate.  An addition to the current model quantifying how 
changes to polymer chemistry affect release might resolve this exception.  However, the accurate 
performance of acylated (ester end-capped) polymer microparticles still provides opportunity for 
the activity analysis of released enfuvirtide with viral infectivity assay.  This single replication 
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cycle infectivity assay confirmed that the delivery of active enfuvirtide was consistent with the 
overall rate of enfuvirtide release.  
The sustained release formulation bypasses the natural tendency of PLGA copolymers to 
provide triphasic release profiles (as described in Section 2.1) by using three such copolymers in 
combinations.  Interestingly a similar strategy was adopted in a recent article where two of 
piroxicam loaded microspheres were combined to extend release, although creation of a linear 
release profile was hampered by limited control over the release behaviors of the building 
blocks
208
.  Sustained release has also been achieved by polymer blends or reduced drying rates, 
which served to broaden PLGA’s polydisperisty68,209.  However, these have proven difficult to 
control and adapt to new manufacturing or performance requirements.  In contrast, the three 
build-blocks used herein work together in unison to sustain macromolecule release.  Further, the 
extensive validation model conducted in Section 3.3.1 suggests that modeling results should 
apply equally well to many other water-soluble peptides or macromolecules in the 3-5kDa range.  
However, one of the three T20 formulations tested deviated from model predictions and requires 
additional discussion. 
The only formulation whose release deviated from predictions during in vitro release 
testing suggests that an additional factor or factors might affect drug release under specific 
conditions.  The most likely explanation is that release of the enfuvirtide peptide (T20) was 
slowed by interacts with the 4.6kDa polymer used in matrix, not accounted for in the initial 
prediction.  In environments of pH < 4.1 enfuvirtide become positively charged, which would 
allow it to interact electrostatically with the carboxylic acid chain ends of the encapsulating 
polymer matrix.  This is supported by the fact that 4.6kDa polymer matrix, which had by far the 
highest concentration of acidic chain ends of all T20 formulations produced, was the only one to 
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show deviation.  If T20 is bound irreversibly to the polymer matrix, it might behave like a large 
protein complex that is predicted to release when the polymer matrix degrades into soluble 
oligomer.  However, T20’s release rate falls in between the predictions for the bound and 
unbound systems (Figure 37A). This behavior is not presently covered by model from chapter 3.  
Retrospective analysis of the model’s correlation between D and Rp points to two outliers, SPF66 
(isoelectric point at pH = 4.8) and leuprolide (isoelectric point at pH = 9.9), that may be affected 
similar interactions.  Further study of peptides with isoelectric points at pH of 4 or greater should 
provide the data needed to better understand how reversible electrostatic interactions effect drug 
release.   
The activity of enfuvirtide, an HIV fusion inhibitor, was quantified in terms of its 
stability and ability to block viral infection. The present work assesses the stability of the peptide 
through analysis of HPLC peaks.  As enfuvirtide degrades, new peaks appear in the HPLC 
chromatograph preceding the original peptide peak and grow in proportion to the concentration 
of each new form of the peptide. Prior work on the detection of enfuvirtide by HPLC has 
identified two truncated forms of enfuvirtide, which also appear in the our data
210
.  The fact that 
these peaks only grow by 10-30% following encapsulation and release is surprising for such a 
large peptide. In literature, peptides and proteins ranging from octreotide acetate to stromal-
derived factor-1 alpha are typically denature, degraded or otherwise inactivated by the double 
emulsion encapsulation process or by the prolonged incubation within the microparticles before 
release
76,94,132,159
.   For example, the stability of octreotide peptide was reduced to 59% and 34% 
of the original following its release from 10kDa and 30kDa 50:50 PLGA microparticles, 
respectively 
132
.  Enfuvirtide’s comparative stability of 83% in the 4.6kDa and 9.0kDa PLGA 
microparticles may arise from its insolubility under the acidic conditions that arise as these 
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polymers degrade
211,212
.  (For the less acidic 33kDa microparticles, a stability of 72% was 
measured upon release.)  Similarly strong stability data have been achieved with solid-in-oil-in-
water (S/O/W) emulsions, where peptides or proteins were encapsulated as dry powders
94,213
.  
However, release from these S/O/W systems is dominated by large initial burst (>60%) because 
the dry powders are difficult to mix uniformly during production and remain near the particle 
surface
94
.  In contrast, the enfuvirtide microparticles developed herein delivered less than 10% 
their payloads in the initial burst because the enfuvirtide was encapsulated in a soluble form and 
is thought to only solidify as the microparticles degrade and become acidic.  These details on 
enfuvirtide stability, however, are only an indicator of activity or the drug’s ability to prevent 
HIV from entering CD4+ cells, which itself can be tested in cell-based assays.    
The single replication cycle cell infectivity assays offer a convenient and sensitive way to 
quantify enfuvirtide activity as well as many other potentially prophylactic drugs that can 
prevent a virus from integrating its DNA into a host chromosome.  The present work used this 
type of assay to measure the infectivity of HIV in the presence of releasate from enfuvirtide 
loaded microparticles and known concentrations of unencapsulated enfuvirtide, which served as 
a control.  Both sample and control groups were pre-incubated with the target TZM cells (HeLa 
cells that expresses CD4, CXCR4 and CCR5 and contains Tat-inducible luciferase reporter) to 
simulate the prophylactic use of enfuvirtide.  A comparable prophylactic assay setup has not 
been previously attempted, but co-incubation of enfuvirtide and HIV-1 isolates with TZM cells 
in prior studies yielded IC-50 ranges of 0.45-22.5ng/ml and IC-90 ranges of 2.25-802ng/ml from 
an assortment of HIV-1 isolates
214
.  The enfuvirtide standards of present work were assayed with 
mixed HIV-1 isolates instead of single isolates.  The resulting IC-50 (11.1 ng/ml) and IC-90 
(139ng/ml) values from this mixture are comparable to the average IC-50 (7.2±8.1ng/ml) and IC-
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90 (312±346ng/ml) of the single isolates tested previously
214
. This result is also consistent with 
data from other HELA cell-based HIV infectivity assays, which establish enfuvirtide IC-50 and 
IC-90 ranges at 4-31.2ng/ml and 67-342ng/ml, respectively, 
215,216
.   
To the best of our knowledge, the present work represents the first instance of a cell-
based assay being used assess the activity of enfuvirtide released from a drug formulation in 
vitro or in vivo.  Prior work on enfuvirtide formulations typically moves directly from in vitro 
release testing to in vivo pharmacokinetic studies where enfuvirtide concentration in serum is 
measured by HPLC
204,205
.  This measurement of intact or stable enfuvirtide is not necessarily the 
same as concentration of active enfuvirtide. The present work uses the TZM cell assay to 
measure the rate of active enfuvirtide release and confirms that it closely follows its in vitro 
release rate as measured by HPLC. This suggests that the enfuvirtide activity also remains 
constant for the duration of release. However, to conclusively determine if stable enfuvirtide is 
active, an infectivity assay (TZM cell or other) would need to be used on enfuvirtide isolated by 
chromatography of in vitro releasate or in vivo serum samples.   
7.5 CONCLUSIONS 
Using enfuvirtide as a representative peptide drug, the sustained release formulation developed 
herein has been evaluated as a platform for the month-long delivery of active agent.  The design 
of the formulation was aided by predictions from the model developed in Chapter 3.0 that 
identified commercially available PLGA polymers which would provide acceptable rates and 
durations of release.  The building-block solution to sustained release by this approach affords 
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flexibility in compensating for the stability of drug in each polymer microparticle component of 
the formulation.  Cell culture testing of enfuvirtide’s ability to prevent infection also confirmed 
the rate of active agent release.  As this result may be due to enfuvirtide’s insolubility in acidic 
environments, further investigations of agent activity would be warranted if this formulation 
were used with other peptides or proteins.   
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8.0  FUTURE WORK  
The studies reported in Chapters 3.0 - 7.0 establish that mathematical models can predict the in 
vitro performance of long-acting controlled release and even be used to expedite their design.  
The utility of this finding is limited by the availability of system-specific predictive models and, 
in the case of formulation design, sensibly defined algorithms that return physically relevant 
critical quality attributes and process parameters.  To this end, significant work remains to be 
done.  The predictive models derived in Chapters 3.0 and 4.0  do not include mathematics for 
describing hydrophobicity or electrostatic interactions.  For instance, the data in Figure 37 
suggests that peptide charge alters release from select polymer matrices.  This effect might be 
difficult to document because the acid environment that arises as microparticles degrade may 
alter the charge of agents with sufficiently high pKa(s).  Mathematics accounting both for 
microparticle acidification and the impact of electrostatic interactions on agent diffusion would 
be needed to predict the release behavior of affected systems.  Another limitation comes from 
matrix size, the lower limit of which has yet to be fully explored.  At nano-scale sizes, the linear 
correlation used to handle autocatalysis may breakdown due to quenching the autocatalytic 
acidic microclime by buffer salts.  When widely accepted and consistent methods of nanoparticle 
manufacture and characterization are developed, it should be possible to conduct mathematical 
validations of their in vitro release behavior and extend existing correlations to cover these 
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systems.  Alternately, it might become practical to integrate expressions describing role of acidic 
catalysts in the degradation of the microparticles.  This would allow changes in particle size and 
agent charge (a function of pH) to be accurately accounted for in future predictions of in vitro 
release and extend the gains in efficiency realized with the current models to a much broader 
range of pharmaceuticals scenarios. 
Certain pharmaceutical scenarios are not effectively represented by in vitro release data. 
Cases that do not involve water-soluble agents being delivered locally (as done in Chapters 6.0 
and 7.0 ) fall into this category. These cases include the large majority of drugs not presently 
delivered by injection and many sparingly or even highly insoluble drugs as well.  Designing 
useful formulations for such drugs requires predictions of systemic drug concentrations in serum 
(i.e. in vivo pharmacokinetic data).  Making accurate in vivo predictions would require a model 
with an extensive record of validation against pharmacokinetic data from controlled release 
formulations.  In developing the models in Chapters 3.0 and 4.0 , nearly 50 data sets from a 
library of over 300 research articles were ultimately used in validation testing.   Building an 
accurate “in vivo” model would also likely require increased knowledge of how the physiological 
environment affects drug release and transport or distribution from depot medications.   Live 
animal imaging (LAI) techniques, such as magnetic resonance imaging, may offer a means of 
monitoring how a dynamic physiological environment spatially and temporally impacts drug 
release. A model developed based on insights from LAI studies could be validated against 
published sets of in vitro and in vivo release data to confirm the accuracy of its predictions.     
Beyond design, predictions of in vitro behavior are useful for the Quality by Design 
manufacturing of controlled release formulations.  Documentation of how manufacturing 
conditions affect in vitro release can help engineers determine if a formulation will be safe to 
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use.  For application to QbD, the system properties used by predictive mathematical models must 
be correlated to the performance of specific manufacturing technologies or facilities.  This may 
prove complicated because tuning occlusion size, matrix geometry and other system properties 
requires experience with specific manufacturing equipment and protocols.  It may also prove that 
multiple aspects of the manufacturing process affect the system properties computed by the 
predictive model.    This is likely the case for polymer molecular weight, which may be altered 
by shear during emulsification or slow drying during lyophilization.  Establishing correlations 
between system properties now computed and the process parameters that affect them will be an 
essential next step in the application of current predictive models to QbD.  This quasi-empirical, 
model-driven approach should prove significantly more efficient than the entirely empirical, 
design of experiments approach now used to generate quality assessments of formulations.  
Beyond the derivation, implementation and application of a model of release for 
hydrolysable polymer matrices, this thesis serves to highlight how a math model can provide 
new ways of addressing challenges in drug delivery.   The increasingly complex scenarios 
presented by environmentally responsive materials, zero-dimensional nanotubes and others as 
well as by new treatment goals may be better resolved by a similarly math model-rich approach.  
Models may prove essential for a number of applications requiring precise temporo-spatial 
control, including the delivery of growth factors for regenerative medicine and the delivery of 
cytokines or chemokines for immunotherapy.  Furthermore, to better incorporate controlled 
release behavior into new therapeutics, models will also be needed for predicting in vivo 
performance of hydrolysable polymer matrices.  Fortunately new techniques, such as live animal 
imaging, may make it easier to measure and compare in vivo release kinetics, helping researchers 
understand how in vitro design tools might be applied to precisely control the concentration of 
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drug in a specific physiological compartment over time.  With continued advances to the design 
“tool-box”, future scientists and engineers may someday tailor controlled release formulations to 
provide specific dosing kinetics to any given physiological compartment by simply selecting 
correct materials and processing methods.  This would pave the way not only to the broad-scale 
production of custom release systems for any application, but perhaps even to patient-specific, or 
“individualized”, controlled release systems that can accompany individualized medicine in the 
future. 
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APPENDIX 
GLOSSARY OF ABBREVIATIONS 
A.1 MODEL VAIRABLES 
CA Concentration of dissolved agent in the polymer matrix 
CAmax Maximum concentration of dissolved agent (solubility limit) 
CAo Initial concentration of dissolved agent 
CS Concentration of solid, crystalline or powdered, agent 
CSo Initial concentration of solid agent in the polymer matrix 
CW Concentration of  water in polymer matrix 
CWo Concentration of  water in the reservoir 
DA Diffusivity of agent through the polymer matrix  
DW Diffusivity of water through the polymer matrix 
ε Matrix porosity 
k Polymer degradation rate 
kdis Agent dissolution rate 
L Length of cylindrical matrix 
Mw Polymer molecular weight 
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Mwo Average initial polymer molecular weight 
Mwr Molecular weight of release 
P(t) Cumulative fraction of agent retained in the matrix at time t 
R(t) Cumulative fraction of agent released from the matrix by time t 
Rocc Occlusion radius 
Rp Matrix dimension(s) across which diffusive release occurs, e.g. 
particle radius, film thickness, or critical length 
σ Variance in Mwr 
t Time 
A.2 POLYMER CHEMISTRIES 
PLGA   poly(lactic-co-glycolic acid) 
PLA   poly(lactic acid) 
SA   sebacic ahydride 
CPH   1,6-bis-p-carboxyphenoxy hexane 
PSA   poly sebacic anhydride 
PFADSA 1:1 Poly(fatty acid dimer-co-sebacic acid) anhydride  
POE  Poly(ortho-ester) 
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